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The molecular culprits driving the atypical clinical variants of Alzheimer’s disease (AD), includ-
ing the recently discovered rapidly progressive AD (rpAD), are unknown to date. Of the several 
mechanisms being studied in this regard, the fibrillization of the amyloid-β (Aβ) peptide is most 
frequently targeted. The Aβ peptide can exist as multiple proteoforms that vary with respect to 
their sequences, post-translational modifications, capabilities to generate amyloids and mecha-
nisms of toxicity. The current study was designed to target these variations in AD patients exhib-
iting classical and rapid progression, with the primary aim of establishing if these variants can 
constitute strains that underlie the phenotypic variability of AD. 
The differences in sequences of pathophysiological proteoforms among sporadic AD (sAD), rpAD 
and non-demented controls were established using hybrid-immunoprecipitation followed by 2D 
gel electrophoresis and top-down MALDI mass spectrometry. A total of 33 Aβ proteoforms were 
identified. Aβ40, Aβ42, Aβ4-42, Aβ11-42 and pyroglutamate Aβ11-42 were common in all AD cases 
however, several shorter N and C-terminally truncated proteoforms showed subtype-specific in-
volvement. sAD showed a greater variety among monomeric species of proteoforms in comparison 
to rpAD. Although no significant differences were evident in the quantities of various Aβ-cleaving 
enzymes that were analyzed to explain the variations in the signature of proteoforms, the ratio of 
β-secretase/α-secretase was significantly higher in rpAD in comparison to sAD indicating higher 
cleavage of Aβ via the amyloidogenic pathway.  
The aggregation of common sAD and rpAD-derived proteoforms and variations in the generated 
fibrils were assessed through a combination of RT-QuIC, Infrared spectroscopy and Atomic force 
microscopy. Although spectroscopy showed that the secondary structure of Aβ fibrils from both 
subtypes of AD was highly similar, the conversion of monomeric species to β-sheet rich fibrils 
was faster in sAD cases in comparison to rpAD. The latter group presented significantly larger 
aggregates highlighting the presence of more hydrophobic, albeit decelerated, Aβ seeds. Applica-
tions of these fibrils to neuronal cells resulted in no significant differences in the survival, impli-
cating that Aβ from sAD and rpAD were equally toxic. Co-IP experiments, on the other hand, 




the former group mainly affected transcription and metabolism while Aβ proteoforms isolated 
from rpAD primarily modulated neurogenesis and neurotransmission.  
This study gives a comprehensive insight into the constituents of Aβ proteome, their relative quan-
tities and their generation in sAD and rpAD brains and, for the first time, establishes differences 
in aggregation kinetics and 3D morphologies of fibrils associated with distinct clinical variants of 
AD. Further validation of reported targets and mechanisms will aid in establishing potential points 






1.1 The Amyloid-beta peptide  
The Aβ peptide is one of the thirty amyloidogenic proteins that are known to cause diseases in 
humans (Knowles et al., 2014). It has been conventionally defined as a 42-residue peptide that is 
produced through the cleavage of amyloid precursor protein (APP). Since its first characterization 
in the 1980s, the genetic, transcriptomic and translational aberrations in APP and its subsequent 
products, especially Aβ, have been an active target of research (Glenner and Wong, 1984; Kang et 
al., 1987).  
1.1.1 Pathophysiological generation of Aβ 
APP undergoes a series of cleavage steps to attain its final conformation, generating several shorter 
functional peptides along the way that are believed to play a role in cell growth and differentiation 
(Clarris et al., 1995). After translation and post-translational processing, APP is trafficked to the 
plasma membrane where a combination of three proteases, the α, β and γ-secretases, modulates its 
processing. Two major routes can be employed for APP processing namely, the amyloidogenic 
and non-amyloidogenic pathway (Haass et al., 2012).  
Under physiological conditions, most of the APP (~90%) is cleaved via the non-amyloidogenic 
pathway. It is initiated by cleavage of APP between residues 687 and 688 by α-secretase. Although 
several enzymes possess α-secretase activity, a disintegrin and metalloprotease domain-containing 
protein 10 (ADAM-10) is most active in the neurons (Kuhn et al., 2010). This cleavage step occurs 
within the Aβ domain of APP, thereby preventing the formation of Aβ. At this step, secreted APP 
alpha (sAPPα) is liberated from the membrane. The remaining 83-residue membrane-bound C-
terminal fragment, C83, undergoes another cleavage via γ-secretase that results in the formation 
of p3 and APP intracellular domain (AICD). A complex containing presenilin-1 (PSEN-1), prese-
nilin-2 (PSEN-2), nicastrin, anterior pharynx-defective-1 and presenilin enhancer-2 constitutes the 
γ-secretase. It has various cleavage sites, including residues 711 and 713 of APP, therefore the 
exact sizes of p3 and AICD fragments vary. sAPPα and AICD are known to function in neuronal 
survival and cell signaling, respectively, however, the function of p3 is not fully understood (Chow 




The cleavage of APP via the amyloidogenic pathway occurs more commonly in neurons in com-
parison to other tissues because of higher amounts of β-site APP cleaving enzyme-1 (BACE-1), 
the major β-secretase, in neuronal tissue. In this pathway, APP is initially cleaved between residues 
671 and 672, releasing secreted APP beta (sAPPβ) and leaving the Aβ domain intact. C99, the 
remaining membrane-bound C-terminal fragment, is further cleaved by γ-secretase releasing Aβ 
and AICD in the cytosol and extracellular environment. sAPPβ plays a role in cell signaling and 
differentiation (Chow et al., 2010). Since only a small percentage of total APP reaches the cell 
membrane, there are several sites within the endosomal pathway and trans-Golgi network where 
the remnant APP is processed. The majority of Aβ is therefore generated intracellularly mainly in 
endoplasmic reticulum (ER), the Golgi apparatus and endosomes where β-secretase and γ-secre-
tase are abundantly present (Haass et al., 2012; Zhang and Song, 2013). The pathways involved in 
the processing of membrane-bound and intracellular APP and the subsequent generation of Aβ are 
summarized in Figure 1.  
Under physiological conditions, Aβ acts as an antimicrobial agent and has also been reported to 
attack oncoviruses and prevent tumors. Additionally, it repairs blood-brain barrier and neuronal 
tissues, thereby aiding in recovery from brain injury. There is also evidence for its role in synaptic 
function and memory consolidation (Brothers et al., 2018). In these cases, the balance between 
amyloidogenic and non-amyloidogenic pathway is strictly maintained and any excess Aβ is de-
graded by insulin-degrading enzyme (IDE), neprilysin (Nep), plasmin, matrix metalloproteases 
(MMPs) and endothelial-converting enzyme (ECE) on the plasma membrane or within lysosomes 
and proteasomes. The shorter fragments generated by these proteases are secreted into the cere-
brospinal fluid (CSF) and lymph (Baranello et al., 2015). Other than neuronal tissue, Aβ is also 
produced in skin, muscles and intestines, but its known toxicity is limited to the brain tissue only 
(Joachim et al., 1989; Citron et al., 1994). 
Like many other proteins in nature, Aβ also exists as several proteoforms. Proteoforms are defined 
as protein products of the same gene that differ with respect to cleavage and other post-translational 
modifications. For several years, the definition of Aβ covered only two major proteoforms, Aβ40 
and Aβ42. They correspond to cleavage of C99 at either residue 711 or 713 by γ-secretase and have 




However, with the advancement in protein extraction and top-down mass spectrometric ap-
proaches, many shorter and post-translationally modified proteoforms have been detected in Aβ-
associated neurodegenerative pathologies (Wildburger et al., 2017). In addition to γ-secretase, 
other enzymes including α-secretase, β-secretase, IDE, ECE and Nep can cleave Aβ at multiple 
sites (Eckman and Eckman, 2005). Additionally, several residues within this peptide can act as 
hotspots for post-translational modifications, thereby aiding the diversity of its proteoforms (Kum-
mer and Heneka, 2014). The generation of fibrils by various components of the Aβ-ome and their 
pathological relevance are an active target of research in the present decade.  
 
Figure 1: Processing of APP and generation of Aβ. The figure presents a summary of APP 
processing via non-amyloidogenic (black arrows) and amyloidogenic (red arrows) pathways 
within the plasma membrane and the subsequent fibrillization of generated Aβ. Aβ is also gener-
ated in ER, Golgi bodies and transport vesicles following the reuptake of APP (red arrows). Under 
physiological conditions, most Aβ is degraded in proteasome and lysosome intracellularly (green 
arrows) and by various proteases on the cell surface before being removed via CSF and lymph. 
1.1.2 Aβ amyloid formation 
The amyloid fibrils are a product of a cascade of events initiated at the formation of altered mon-
omeric species due to mutations, aberrant cleavage or environmental factors that lead to cellular 




processing enzymes or inefficient clearance contributes towards this cascade. Aβ is an intrinsically 
disordered peptide and under physiological conditions, α-helical domains dominate its secondary 
structure. However, under circumstances that are still not understood, deprotonation of resident 
amino acids collapses the native structure by breaking the backbone of the helix and prompting 
interactions between side chains (Ito et al., 2011). The peptide then refolds into a compact β-sheet 
rich secondary structure that is stabilized by the presence of electrostatic interactions.  
The conversion of native helical structure to a thermodynamically favorable β-sheet-rich confor-
mation is also known as ‘monomer activation’. These misfolded units can self-replicate by inter-
acting with physiological Aβ peptides and altering their conformation. The combination of these 
altered structures, or primary nucleation, leads to the formation of an aggregate that can seed the 
formation of amyloid fibrils (Gillam and MacPhee, 2013). These seeds undergo a repetitive cycle 
that involves the assembly of multiple toxic oligomeric species leading to the formation of various 
multimers, protofibrils (2.5 to 3 nm in diameter), and fibrils (a combination of two strands with a 
diameter of 6 to 10 nm; Khurana et al., 2003). The primary event of nucleation and fibril formation 
is relatively slow and is referred to as the lag phase of growth. The intertwining of protofibrils and 
fibrils leads to the formation of mature fibrils that are 60-120 nm in diameter (Figure 2; Serpell, 
2000). X-ray diffraction and nuclear magnetic resonance analysis showed spacing of approxi-
mately 10 Å between the layers of beta-sheets and approximately 4.7 Å between multiple β-strands 
depicting a uniform and stable assembly (Gillam and MacPhee, 2013). The addition of monomers 
to fibrils changes their conformation so that it matches with the residues present in the aggregates 
leading to the growth of amyloid fibrils, a step referred to as ‘secondary nucleation’ (Scheidt et 
al., 2019). At this point, the growth of amyloid fibrils reaches an exponential phase causing rapid 
accumulation of aggregates. 
In contrast to its native counterpart, this β-sheet structure is highly hydrophobic. Consequently, 
the functions of various domains within this structure also change. The residues 1-13 constitute 
the metal-binding domain, residues 15 and 21 have the aggregation core while residues 25-35 are 
required for exerting neurotoxic effects thereby constituting the functional domains. The C-termi-
nal tail is critical for the conversion of native α-helical structure to amyloids (Chen et al., 2017). 




neuronal transfer and spread the disease pathology from the primary site of amyloid formation, 
usually the posterior cortex, to other regions of the brain (Palmqvist et al., 2017; Sinha et al., 2018).  
 
Figure 2: Structure of fibrils generated via in vitro aggregation of synthetic Aβ40. Protofibrils 
twist around each other to form thicker ribbon-like fibrils, as observed by negative stain electron 
microscopy following in vivo fibrillization of Aβ40 (Zafer et al., submitted). Scale bar represents 
100 nm. 
Aβ amyloid formation is a dynamic process and there is a room for heterogeneity at various steps. 
Different proteoforms of Aβ vary with respect to their aggregation propensity and kinetics. Heter-
ogeneity has also been reported in the exact three-dimensional conformation adopted by Aβ fibrils 
depending on aggregating proteoform and surrounding conditions (Sgourakis et al., 2007). Early 
X-ray diffraction experiments showed that Aβ19-28, Aβ13-28, Aβ12-28, Aβ11-28, Aβ9-28, Aβ1-28, Aβ1-38, 
Aβ1-40, Aβ6-25, Aβ11-25 and Aβ34-42 form fibrillar assemblies with hydrogen bonding in the direction 
of fiber axis resulting in highly ordered crystalline lattices. Aβ18-28, Aβ17-28, and Aβ15-28, on the 
other hand, form plate-like assemblies extending in both directions, while peptides Aβ22-35 and 
Aβ26-33 have fibrillar assemblies with no preferential direction presenting circular scattering (In-
ouye et al., 1993). Moreover, although the β-sheet-rich oligomers and amyloids have been targeted 
for decades with respect to the prevention of neurotoxicity, a recent study suggests that oligomers 
with non-traditional secondary structures, like α-sheets, are also prone to amyloid formation and 
cause neurotoxicity (Shea et al., 2019). The direct consequences of this heterogeneity are still not 
understood, but it may lead to differences in pathology and the resulting disease phenotypes (Ras-




The survival of amyloids and their ability to escape the cell’s quality control checkpoints to prop-
agate uncontrollably can be attributed to their structure that is rich in cross-β sheets and creates an 
opportunity for the continuous formation of hydrogen bonds, imparting stability to the overall 
structure (Knowles et al., 2014). These structures have been reported to cause around fifty different 
human diseases that are known by many names (neurodegenerative proteinopathies, protein con-
formational diseases, prion diseases, aggregopathies and amyloidosis), all explaining the underly-
ing dogma of aggregating proteins. Although amyloids formed by many different proteins follow 
the same pathways for propagation and form similar structures, the exact mechanisms of toxicity 
depend on the amyloidogenic protein involved. Several mechanisms have been proposed for Aβ-
induced toxicity, as discussed in the following section.  
1.1.3 Aβ-associated neurotoxicity 
Proteins can exist in various states within the living systems, however their functionality can only 
be attributed to their specific three-dimensional structures. They have been known to form highly 
ordered structures containing defined conformations and domains that interact with cofactors and 
binding partners to bring about the required function. Any alterations in their conformations can 
have drastic effects on cells and the amyloid structures serve as a perfect example of this phenom-
enon. The conversion of Aβ from predominantly α-helical secondary structure to fibrils and amy-
loids changes its pro-survival roles to severely pathological activities.  
Aβ can manipulate several pathways that lead to apoptosis and neuronal loss. Several species 
formed during the amyloidogenesis of Aβ have been tested for relative toxicities. Ever since the 
discovery of Aβ, it was believed that Aβ fibrils are major species that inflict toxicity, however, 
mounting evidence suggests that plaque-associated fibrillar Aβ may have a protective role (Davis-
Salinas and Van Nostrand, 1995; Wujek et al., 1996). It sequesters the oligomeric and protofibrillar 
Aβ, species that are now believed to be toxic, and prevents them from inflicting damage to the 
cells. Conversely, plaques may also act as the reservoir for a constant supply of Aβ, aiding in its 
neurotoxic effects (Reiss et al., 2018). Although the relative toxicities of various Aβ species are 
still controversial, the mechanisms involved in Aβ-associated neurotoxicity are now partly under-





Figure 3: Known neurotoxic effects of various Aβ species. Misfolded Aβ species confer their 
neurotoxic effects via multiple pathways. Synaptic dysfunction and neuronal death by induction 
of oxidative stress, mitochondrial aberrations, pore formation and receptor obstruction are some 
of the most frequently reported mechanisms of Aβ-associated toxicity and have been detailed in 
this figure. 
1.1.3.1 Aberrations in membrane permeability  
Aβ can target lipid bilayer by forming channel-like structures that impair the permeability of the 
plasma membrane (Pollard et al., 1993). Calcium (Ca2+) and potassium (K+) ions can pass through 
these channels freely (Mattson et al., 1993; Etcheberrigaray et al., 1994). Aberrant ion homeostasis 
impairs the strictly regulated ion gradient, especially that of Ca2+, within the neurons, triggering 
pathways that lead to mitochondrial dysfunction, oxidative stress and cell death (Dykens et al., 
1994). 
1.1.3.2 Oxidative stress 
The neuronal tissue houses abundant amounts of copper (Cu), iron (Fe) and zinc (Zn) which func-
tion as modulators of protein activity and cell signaling. Under physiological conditions, their con-
centrations and redox states are tightly regulated (Cheignon et al., 2018). The Aβ peptide, specif-
ically the methionine residue at position 35 within Aβ, possesses the capability to reduce Cu and 




peroxide in the process (Yatin et al., 1999; Rival et al., 2009). These radicals oxidize DNA, pro-
teins, lipids and neurotransmitters within the neurons and disrupt various physiological processes 
(Gabbita et al., 1998; Hardas et al., 2013; Granold et al., 2015).  
1.1.3.3 Mitochondrial dysfunction 
Mitochondrial dysfunction is abundantly seen in Aβ-associated pathologies. Interaction of Aβ with 
mitochondria increases the formation of reactive oxidative species (ROS) by Aβ-induced down-
regulation of respiratory enzymes and disruption of electron transport chain (Hernandez-Zimbron 
et al., 2012). Moreover, the mitochondrial membrane potential is disrupted, and mitochondrial 
fission is promoted in Aβ-treated cells (Han et al., 2017). Together, these effects deprive the neu-
rons of energy, thereby aiding another mechanism of cellular dysfunction and death. 
1.1.3.4 Synaptic dysfunction 
The neurotoxic effects of Aβ on memory and behavior precede neuronal loss owing to its effects 
on synapses and neurotransmission. Misfolded Aβ, mainly in oligomeric form, possesses the ca-
pability to bind with various synaptic receptors, including glutaminergic (N‐methyl‐d‐aspartate 
(NMDA), α‐amino‐3‐hydroxyl‐5‐methyl‐4‐isoxazole‐propionate (AMPA), metabotropic) and 
cholinergic (both α7 nicotinic and muscarinic receptors) receptors, and functions by either desen-
sitizing or internalizing them. The most profound effects observed as a result of this binding are 
the inhibition of long-term potentiation, impaired long-term depression, loss of cholinergic trans-
mission, decreased synaptic plasticity and inefficient memory retrieval. Consequently, relative 
amounts of certain Aβ species correlate with loss of spatial memory in rodent models (Esposito et 
al., 2013; Rajmohan and Reddy, 2017). The generation of ROS by Aβ and frequent activation of 
glutaminergic receptors have been proposed to contribute towards calcium dyshomeostasis, lead-
ing to excitotoxic damage and neuronal loss (Mattson et al., 1992; Harris et al., 1995). Addition-
ally, Aβ also contributes to synaptic dysfunction by reducing mature dendritic spines and impact-
ing vesicular transport (Ovsepian et al., 2018; Reiss et al., 2018).  
1.1.3.5 Modulation of signaling pathways 
Synaptic receptors are not the only receptors obstructed by Aβ. Its interplay with receptor for ad-
vanced glycation end products (RAGE), cellular prion protein (PrPC) and insulin receptors also 




Nuclear factor kappa-light-chain-enhancer of activated B cells, tyrosine-protein kinase Fyn, mito-
gen-activated protein kinase and serine/threonine-protein kinase Akt-1 are aberrantly activated as 
a result of these interactions and impair processes involved in axonal growth, cell survival, inflam-
mation, and transcription (Zhao et al., 2008; Smith et al., 2017). Hyperphosphorylation of tau and 
the subsequent formation of neurofibrillary tangles (NFTs) are also products of aberrant activation 
of previously mentioned kinases or oxidative stress and hold great pathological relevance in sev-
eral neurodegenerative diseases (Zempel et al., 2010; Lloret et al., 2011).   
1.2 Alzheimer’s disease and Aβ  
AD is the most common form of dementia and affects approximately one tenth of the elderly pop-
ulation above 65 years of age (Gaugler et al., 2019). The formation of Aβ fibrils and their accu-
mulation as senile plaques constitute one of the two major molecular hallmarks of AD, the other 
one being the presence of intracellular tau tangles. Since the first case study by Alois Alzheimer, 
evidence that favors the key role of Aβ in AD has grown drastically, however, the exact relation-
ship between Aβ deposits, tau tangles and AD-associated cognitive decline is still not established 
(Alzheimer, 1907). Over the years several ideas have been presented for the placement of Aβ-
induced neurotoxicity and other key features of AD, some of which are stated as follows (Du et 
al., 2018; Kinney et al., 2018; Pardo, 2019); 
1. Amyloid cascade hypothesis: This hypothesis is one of the earliest ones explaining the 
pathophysiology of AD and states that mismetabolism of Aβ and the subsequent fibril for-
mation initiates AD. 
2. Oligomer hypothesis: Primarily an extension of amyloid cascade hypothesis, this hypoth-
esis states that oligomeric species, instead of fibrils, are the primary culprits behind AD.  
3. Tau hypothesis: In comparison to its former counterparts, this school of thought focuses 
on the second molecular hallmark of AD, the tau tangles, and states that tau pathology 
precedes Aβ deposition and causes AD. 
4. Inflammation hypothesis: According to this hypothesis, aberrant activation of microglia-
associated pathways modulates Aβ and tau pathology and drives AD. 
5. Oxidative stress hypothesis: This hypothesis acknowledges Aβ-induced mitochondrial 




6. Metabolic syndrome hypothesis: This idea suggests that AD is a product of age-associ-
ated aberrations in cerebral glucose metabolism and leads to deposition of Aβ.  
Nevertheless, every hypothesis acknowledges the involvement of Aβ in AD, either as a cause or 
consequence of underlying pathology, due to several known facts. Firstly, mutations in APP and 
Aβ-processing enzymes, PSEN1 and PSEN2, are major causes of the familial variant of this dis-
ease (Goate et al., 1991; Haass, 1996; Plassman and Breitner, 1996). Similarly, genetic interven-
tions to mutate these genes cause AD-like pathology in experimental models (Kitazawa et al., 
2012). Moreover, directly injecting brain-derived Aβ in rodents also leads to neurodegeneration 
(Ruiz-Riquelme et al., 2018). Lastly, clinical studies show that the presence of Aβ plaques in fron-
toparietal regions of the brain precedes tau pathology and cognitive symptoms of the disease, in-
dicating its pivotal role in disease pathology (Figure 4). 
 
Figure 4: Proposed timeline of AD-associated changes in the brain. Aberrations in CSF Aβ 
levels and appearance of plaques precede tau pathology, brain atrophy and cognitive symptoms, 
indicating the pivotal role of Aβ pathology in AD (Stanley et al., 2016). 
However, the repeated failures of Aβ-targeting drugs and the presence of Aβ deposits in non-
demented individuals question Aβ-related hypotheses of AD and give some evidence in the favor 
of other hypotheses (Rodrigue et al., 2009; Du et al., 2018). The identification and isolation of 
clinically relevant Aβ proteoforms and conformers is therefore necessary.  
1.2.1  Clinical features of classical AD 
Clinically, AD is defined as memory impairment accompanied by changes in executive function, 
visuospatial capability, speech, behavior and/or movement. Although a definite diagnosis is still 
not possible before the autopsy, the following criterion is utilized for diagnosis of probable AD 




1. Decline of three Mini-Mental State Examination (MMSE) points/year 
2. Increased tau/phospho-tau (p-tau) and decreased Aβ42 levels in CSF 
3. Reduced hippocampal volume 
4. Hypometabolism in the parietal lobe, temporal lobe and hippocampus 
5. Positive amyloid positron-emission tomography  
The patients with early AD present problems with recent episodic memory followed by the devel-
opment of progressive anomia. Aphasia is the next symptom to be reported in most cases along 
with dysexecutive syndrome. Psychiatric symptoms, including irritability, delusions and halluci-
nations, are also reported. In the final stages, the patient loses mobility and death occurs due to 
complications associated with the aforementioned symptoms. The patients survive between 8 to 
10 years from the onset of symptoms, as currently there is no cure available for AD (Tang-Wei et 
al., 2005). The symptoms are managed by acetylcholine esterase inhibitors and memantine (Shao, 
2015).  
1.2.2  Clinical variants of Alzheimer’s disease 
AD is a complex disease that features several different clinical variants based on the age of onset, 
pathological burden, cognitive decline and psychiatric symptoms, some of which are discussed as 
follows.  
1.2.2.1 Familial AD 
Although the age of onset in most cases is around 65 years, onset has been observed in a small 
fraction of patients (1%) as early as 46 years. These cases generally have the familial or autosomal 
dominant variant of AD (fAD) with mutations in APP, PSEN1, PSEN2 or one of the other 31 risk 
genes (Moustafa et al., 2017). Heterogeneity within this variant arises from the differential presen-
tation of cognitive symptoms in cases with different mutations (Ryan et al., 2016).  
1.2.2.2 Sporadic AD 
Early-onset AD (EOAD) has also been observed without genetic causes and constitutes 5% of all 
AD cases. However, most cases present late-onset AD (LOAD). Both EOAD and LOAD occur 
due to sporadic causes, but diabetes mellitus, obesity, smoking, lack of activity and ApoE genotype 




1.2.2.3 Atypical variants of AD  
Depending on the affected brain regions, AD can feature an atypical combination of symptoms. 
Posterior cortical atrophy is frequently associated with AD pathology in visual association areas 
and presents worse visual deficits. Similarly, primary progressive aphasia features AD pathology 
in conjunction with language impairment. Aβ deposits and tau pathology are also common in pa-
tients of other neurodegenerative diseases like Parkinson’s disease (PD), Creutzfeldt–Jakob dis-
ease (CJD), Gerstmann-Sträussler Syndrome (GSS), dementia with Lewy bodies (DLB), and fron-
totemporal dementia (FTD; Mastaglia et al., 1989, Haltia et al., 1991; Amano et al., 1992, Bar-
cikowska et al., 1995, Forman et al., 2006). 
1.2.2.4 Rapidly progressive dementia with AD pathology  
Rapidly progressive dementias constitute a small subset of dementia patients that are characterized 
by reports of dementia within 1-2 years (weeks in some cases) of disease onset. The short duration 
of the disease gives an even shorter window for accurate diagnosis and treatment, presenting a 
challenge for neurologists and biomedical researchers alike. However, if diagnosed in time, many 
cases are treatable. The most common causes of rapid progression include vascular anomalies, 
infections, toxic-metabolic causes, autoimmune diseases, metastasis, iatrogenic causes, neuro-
degenerative disorders and seizures (Paterson et al., 2012). Although the exact contribution of each 
of these causes towards the incidence of rapidly progressive dementias is variable in reports from 
different centers, most cases are attributed to autoimmune diseases and neurodegenerative pathol-
ogies. Within the latter untreatable cause, prion diseases, AD and FTD are the most common con-
tributing pathologies. Corticobasal syndrome and DLB also contribute towards rapidly progressive 
dementias (Poser et al., 1999; Papageorgiou et al., 2009; Neto et al., 2017; Geut et al., 2019).  
Owing to its contribution towards the etiology of rapidly progressive dementia, rpAD has now 
been recognized as an atypical clinical variant of AD. The first paper about rpAD was published 
in 1989, followed by other reports where AD was misdiagnosed as CJD due to rapid deterioration 
in memory and shorter survival time (Mann et al., 1989; Poser et al., 1999; Reinwald et al., 2004). 
Although rpAD researchers and neurologists have not reached a consensus regarding the clinical 
definition of this disease, many use a decline of at least 6 MMSE points per year and disease 
duration of less than 3 years (2 years in some centers) as a diagnostic criterion (Figure 5; Abu-





Figure 5: Differences among sAD and rpAD. rpAD follows the same clinical course as classical 
AD, hereafter referred to as sAD, but the progression is faster and the survival is usually less than 
three years from the onset of symptoms.  
1.2.2.4.1 Clinical and molecular differences in sAD and rpAD  
Several differences have been observed in clinical course and biomarker profiles among sAD and 
rpAD cases. Neurological signs, including executive dysfunction, language impairment and move-
ment disorder, are observed earlier during the disease course in rpAD cases. Moreover, these cases 
show higher levels of tau and p-tau along with reduced Aβ42 in CSF in comparison to sAD, how-
ever, the utility of these biomarkers to differentiate sAD from rpAD is still debatable (Llorens et 
al., 2016). 14-3-3, on the other hand, is only present in rpAD cases and can be used for differential 
diagnosis (Schmidt et al., 2010; Schmidt et al., 2012, Karch et al., 2016). On an anatomic level, 
no significant differences are observable in brain atrophy and hippocampal volume. In the context 
of risk factors, APOE ε4 allelic frequency appears to be lower in rpAD cases in comparison to 
sAD (Ba et al., 2017; Pillai et al., 2018).  
The molecular mechanisms behind rapid progression observed in rpAD are yet to be elucidated. 
Markers for inflammation (cartilage glycoprotein YKL-40), tissue damage (α-synuclein) and ax-
onal damage (neurofilament light) show no significant differences among sAD and rpAD cases. 
Moreover, no differences in distribution and structures of plaques and NFTs have been reported 
(Schmidt et al., 2012). Rapid progression has been attributed to higher levels of PrPC, a known Aβ 
receptor, although its levels are also not significantly different among the two variants (Abu-Ru-




been validated in rpAD (Zafar et al., 2017). On the proteomic level, plaques in rpAD have several 
proteins associated with synaptic dysfunction along with fewer active plaque-clearing astrocytes 
(Drummond et al., 2017). 
1.3 Sub-populations of Aβ and clinical variants of AD 
Understanding the existence of multiple clinical variants of AD with seemingly similar underlying 
pathology and key molecular players requires immense research efforts. What causes Aβ and tau 
to behave differently and initiate pathologies that not only have different clinical features but also 
alter the rate of progression of the disease? The answer, although still not completely understood, 
may lie in the strain theory of prion disorders.  
Prion is defined as a proteinaceous infectious particle that assembles into fibrillar assemblies. Scra-
pie isoform of the cellular prion protein (PrPSc) is one of the thirty pathological amyloidogenic 
proteins and is best known for its involvement in CJD, GSS and several other debilitating human 
and animal neurodegenerative diseases. The conversion of PrPC to PrPSc also follows the same 
mechanism as Aβ amyloid formation. However, although the underlying mechanism and patho-
logical protein are similar, several variants of prion disease are known to exist (Collinge et al., 
2001). This heterogeneity has been attributed to the existence of distinct PrP strains. Strains are 
defined as conformers of a specific amyloidogenic protein, in this case PrPSc, that differ with re-
spect to their transmission, brain-lesion profiles, incubation periods and disease phenotypes along 
with certain biochemical characteristics like post-translational modifications, sensitivity to pro-
teinase K and electrophoretic mobility. The distinct conformational characteristics of each PrP 
strain are transmitted into the host, where it propagates and causes distinct phenotypes (Morales, 
2017). The codon 129 polymorphism gives rise to at least three known strains of PrP in humans 
(Lewis et al., 2006). The strain theory is also applicable to tau and α-synuclein (Petersen et al., 
2019; Jaunmuktane and Brandner, 2019).  
In case of Aβ, it has been known for several years that different proteoforms vary in their capability 
to form amyloids, seeding proficiencies, three-dimensional conformations, transport mechanisms 
and toxicities (Burdick et al., 1992; Rush et al., 1992; Pike et al.,1995; Martel et al., 1996). Each 
proteoform can adopt and propagate in multiple conformations (Chakraborty and Das, 2017). 




bilities, distribution and morphology in the brain. They are transmissible among humans and be-
tween humans and animals (Rasmussen et al., 2017). These variants fulfill the definition of strains, 
hence, similar to prion disease, the heterogeneity of clinical phenotypes of AD can be attributed to 







1.4 Aims of the study 
The current study was designed to apply the strain theory of prions to AD and characterize sAD 
and rpAD based on differences in Aβ proteoforms and associated conformers. We hypothesized 
that certain variants of Aβ, their sequences, structures or interactions, may be responsible for the 
faster progression observed in rpAD. In contrast to studies conducted by other groups, we under-
took the challenging task of purifying the extremely hydrophobic and insoluble Aβ peptides gen-
erated in the endogenous environment. Brain-derived Aβ peptides were extracted using affinity 
purification and subsequently subjected to various proteomic methods for their identification and 
quantification. The fibrils produced by aggregation of these proteoforms were extracted using mild 
protein purification techniques and amplified via in vitro aggregation assays before their biophys-
ical analysis. For a comprehensive characterization of these clinical variants of AD three different 
aspects of Aβ biology were targeted in this work, and the major aims were as follows:  
1. evaluate the alterations in the primary sequence of Aβ proteoforms isolated from sAD and 
rpAD brains, 
2. establish differences in the three-dimensional (3D) architecture of brain-derived Aβ con-
formers, and 
3. define the functional consequences of alterations in Aβ proteoforms and conformers among 
the targeted clinical variants of AD.  
 
 




2. Materials and Methods 
2.1 Materials  
2.1.1 Antibodies 
The antibodies used for immunoprecipitation (IP) and immunoblot (IB) analysis in this study are 
listed in Table 1. 
Table 1: List of primary and secondary antibodies utilized in the current study. 






4G8 Aβ IgG2b Mouse  1:1000 1:100 BioLegend/800701 
6E10 Aβ IgG1 Mouse  1:1000 1:100 BioLegend/803001 
ADAM-10 IgG Rabbit  1:1000 - Abcam/ab124695 
BACE-1 IgG Rabbit  1:1000 - Abcam/ab108349 
PSEN-1 IgG2a Mouse  1:200 - Santa Cruz Biotechnol-
ogy/ sc365495 
PSEN-2 IgG1 Mouse  1:200 - Santa Cruz Biotechnol-
ogy/ sc393758 
Nicastrin IgG1 Mouse  1:200 - Santa Cruz Biotechnol-
ogy/ sc376513 
IDE IgG1 Mouse  1:200 - Santa Cruz Biotechnol-
ogy/ sc393887 







Goat 1:10000 - JacksonIR Lab/ 115-035-
062 







Goat 1:10000 - JacksonIR Lab/ 111-035-
144 
 
2.1.2 Chemicals  
Unless stated otherwise, the chemicals used for this study were obtained from either Sigma 
(Deisenhofen, Germany), Merck (Haar, Germany), Serva (Heidelberg, Germany), Roth (Karls-
ruhe, Germany) or Bio-Rad (Munich, Germany). 
2.1.3 Peptides, standards, enzymes and kits 
The peptides, standards, enzymes and kits used in the current study are listed in Table 2. 
Table 2: List of peptides, standards and kits used in this study.  
Product Company/ Cat. No. Purpose 
Aβ40 peptide Abcam/ ab120479 In vitro seeding assays 
Aβ42 peptide Abcam/ ab120301 In vitro seeding assays 
Precision Plus Protein standards Bio-Rad/ 161-0374 Standard for IB 
Peptide calibration standard  Bruker/ 8222570 Calibration of MALDI-
ToF MS spectrum 
DNase I Thermo Fisher Scientific/ 
EN0521 
Protein purification 
Sequencing grade trypsin Serva/ 37283 Protein digestion 
Protease inhibitor Roche/ 4693116001 Protein extraction 
Phosphatase inhibitor Roche/ 04906837001 Protein extraction 
40% Biolyte 3-10 ampholytes Bio-Rad/1631112 Isoelectric focusing (IEF) 
Dynabeads protein G Invitrogen/ 10003D IP 
Bradford’s reagent Bio-Rad/ 500-0006 Protein quantification 
MemCode reversible 
protein stain kit 
Pierce/ 24580 IB normalization 
Aβ1-x ELISA  IBL International/ JP27729 Quantification of Aβ 
Aβx-42 ELISA Biolegend/ 842401 Quantification of Aβ 




Aβ1-40 ELISA Biosource/ MBS760432 Quantification of Aβ 
MTS assay kit Abcam/ ab197010 Cell viability assays 
 
2.1.4 SH-SY5Y cells and culture media 
SH-SY5Y cells were a kind gift from the Institute of Neuropathology, Saarland University Hospi-
tal, Homburg, Germany. Dulbecco’s modified Eagle’s medium (DMEM; Sigma, Germany) was 
supplemented with 10% fetal bovine serum (FBS; Sigma, Germany), 1% mixture of penicillin and 
streptomycin (P/S; MP biomedicals, Germany) and 1% L-glutamate (Gibco, Germany) was used 
for the maintenance of the culture at  37°C, under 5% CO2 and 95% humidity. All flasks, plates 
and other cell culture consumables were obtained from Sarstadt, Germany.  
2.1.5 Laboratory instruments and other materials 
The laboratory instruments and other materials used for various experiments are enlisted in Table 
3.  
Table 3: List of laboratory instruments and other materials used for this study 
Instrument Model Manufacturer 
Tissue lyser 85600 Qiagen, Germany. 
Tenbroeck tissue grinder LG-10660-100 Wilmad-LabGlass, USA. 
Sonicator T310/H Elma, Switzerland. 
Spectrophotometers Ultospec 2100 Pro Amersham Biosciences, UK. 
NanoDrop™ 1000  Thermo Fisher Scientific, 
Germany. 
Spectrum 100  Perkin Elmer, USA. 
Thermomixer 5436 Eppendorf, Germany. 
Centrifuges 5810R Eppendorf, Germany. 
Optima TL100 Beckmann coulter, Germany. 
Speed Vac SVC 100 Savant, USA. 
PROTEAN IEF Cell 1646001 Bio-Rad, Germany 
IPG strips (3-10 non-linear) 1632002 Bio-Rad, Germany. 
Mini-PROTEAN Tetra cell 10007296D Bio-Rad, Germany. 




Mini Gel Tank A25977 Invitrogen, USA. 
4-20% Bis-Tris gradient gels NP0330BOX Invitrogen, USA. 
Power supply Power Pac 300 Bio-Rad, Germany. 
Transfer Cell Trans-blot Turbo 1704150 Bio-Rad, Germany. 
TE 77 PWR AA Hoefer, USA. 
Amersham Hybond P Polyvi-
nylidene fluoride (PVDF) 
membranes 
10600021 (0.2 μm) Sigma-Aldrich, USA. 
10600023 (0.45 μm) Sigma-Aldrich, USA. 
Amersham Hybond® P nitro-
cellulose membranes 
10600002 (0.45 μm) Sigma-Aldrich, USA. 
ChemiDoc XRS+ 170-8265 Bio-Rad, Germany. 
Plate Readers Wallac Victor 1420-002 Wallac, Finland. 
FLUOstar Omega BMG Labtech, Germany. 
Microscopes Axiovert 25 Carl Zeiss, Germany. 
Zeiss LSM 510 Meta Carl Zeiss, Germany. 
MFP-3D Infinity  Asylum Research, USA. 
Hydraulic Press 15011 Specac, UK. 
Biosafety cabinet Herasafe HS 15 Thermo Fisher Scientific, 
Germany. 
Waterbath WNB22 Memmert, Germany. 






Bruker Daltonics, USA. 
C18 columns precolumns 20 mm x 0.15 mm ID Thermo Fisher Scientific, 
Germany. 
PicoFrit revesed phase C18 
columns 
PF360-75-15-N-5 New Objective, USA. 
Nanoflow chromatography 
system 
Easy nLC-1000 Thermo Fisher Scientific, 
Germany. 






Q Exactive Hybrid Quadru-
pole-Orbitrap mass spectrom-
etry system 
Thermo Fisher Scientific, 
Germany. 
 
2.1.6 Software  
The following software (Table 4) were employed for visualization and analysis of data in the cur-
rent study.  
Table 4: List of software used in the current study. 
Software Application Version Developer  
Image Lab IB analysis 6.0.1 Bio-Rad, Germany. 




4.8 Decodon GmbH, Germany. 
Igor Pro Atomic force micros-
copy (AFM) 
6.37 WaveMetrics, USA. 
Gwyddion  AFM analysis 2.53 Czech Metrology Institute, 
Czech Republic. 
Zeiss LSM Confocal microscopy 4.2.0.121 Microimaging GmBH, Ger-
many. 
ImageJ Confocal microscopy 1.52 National Institute of Health, 
USA 
Spectrum FTIR spectroscopy 6.10 Perkin Elmer, USA. 
FlexImaging MALDI 4.1 Bruker Daltonics, USA. 
FlexAnalysis MALDI analysis 3.4 Bruker Daltonics, USA. 
Excalibur ESI-MS/MS 3.1.6.1 Thermo Fisher Scientific, Ger-
many. 
Raw2MSM ESI-MS/MS 1.17 University of Southern Den-
mark, Denmark. 




Mascot ESI-MS/MS 2.5.1 Matrix science, UK. 
Scaffold  ESI-MS/MS 4.8.9 Proteome Software Inc., USA. 
PRISM Statistical analysis 6.0 GraphPad Software, USA. 
RStudio Statistical analysis 1.1.383 RStudio, Inc., USA. 
  
2.1.7 Stock solutions 
Lysis Buffers: 
Urea-Thiourea Lysis buffer: 7 M Urea, 2 M thiourea, 4% 3-[(3-cholamidopropyl)-dime-
thylammonio]-1-propane sulfonate (CHAPS), 2% ampholytes, 1% dithiothreitol (DTT), phos-
phatase and protease inhibitors in dH2O. 
Tris-Triton Lysis Buffer: 50 mM Tris-HCl pH 8.0, 0.5% CHAPS, 1 mM ethylenediaminetet-
raacetic acid (EDTA), 1 mM DTT, 1% Triton-X100, phosphatase and protease inhibitors in 
dH2O. 
Solutions for one-dimensional polyacrylamide gel electrophoresis (1D-PAGE): 
Laemmli buffer (4x): 0.25 M Tris-Cl, 8% sodium dodecyl sulphate (SDS), 40% glycerol, 20% 
β-mercaptoethanol and 0.008% bromophenol blue in dH2O (pH 6.8). 
Stacking Gel buffer: 0.5 M Tris-base and 0.4% SDS in dH2O (pH 6.8). 
Resolving Gel buffer: 1.5 M Tris-base and 0.4% SDS in dH2O (pH 8.8).  
Electrophoresis buffer: 192 mM Glycine, 0.1% SDS and 25 mM Tris-HCl in dH2O (pH 8.3). 
Solutions for IEF: 
Elution Buffer for IP/ Rehydration buffer: 8.3 M Urea, 0.5% CHAPS, 20 mM DTT and 0.5% 
(v/v) ampholytes in ddH2O. 
Equilibration buffer I: 6 M Urea, 2% SDS, 30% glycerin, 0.375 M Tris-base (pH 8.8), 2% 
(w/v) DTT in ddH2O. 
Equilibration buffer II: 6 M Urea, 2% SDS, 30% glycerin, 0.375 M Tris-base (pH 8.8), 2.5% 
(w/v) IAA and bromophenol blue in traces in ddH2O. 
Solutions for native polyacrylamide gel electrophoresis (native PAGE): 




Sample buffer (2x): 62.5 mM Tris-Cl, 25% glycerol and 0.01% bromophenol blue in dH2O (pH 
6.8). 
Stacking Gel buffer: 2.5 M Tris-base in dH2O (pH 6.8). 
Resolving Gel buffer: 1.5 M Tris-base in dH2O (pH 8.8).  
Electrophoresis buffer: 192 mM Glycine and 25 mM Tris-HCl in dH2O (pH 8.3). 
Solutions for Western blot: 
Tris-Glycine Transfer buffer: 48 mM Tris-base, 39 mM glycine, 1.0 mM SDS and 20% meth-
anol in dH2O (pH 8.3). 
Tris-Glycine Transfer buffer for Aβ: 25 mM Tris-base, 190 mM glycine and 20% methanol 
in dH2O (pH 8.3). 
Phosphate-buffered saline with Tween-20 (PBS-T): 9.55 g/L PBS and 0.0005% tween-20 in 
ddH2O. 
Blocking Buffer: 5% Milk powder in PBS-T. 
Enhanced chemiluminescence (ECL) solution: 0.15 M Tris-HCl (pH 8.5), 1.25 mmol luminol, 
0.55 mmol coumaric acid and 0.0003% hydrogen peroxide in dH2O. 
Reblotting Buffer: 0.2 M Glycine, 3.5 mM SDS, 1% Tween-20 (pH 2.2) in dH2O. 
Solutions for Coomassie Staining:  
Fixative solution: 50% Methanol in 12% acetic acid in ddH2O. 
Coomassie G-250 solution: 0.25% Coomassie G-250 in the fixative solution. 
Destaining solution: 10% Acetic acid, 10% methanol in ddH2O. 
Solutions for Silver Staining:  
Fixative solution: 50% Methanol, 12% acetic acid in ddH2O. 
Sensitization solution: 0.8 mM Sodium thiosulphate in ddH2O. 
Staining solution: 0.2% Silver nitrate and 0.026% formaldehyde in ddH2O. 




Developing Solution: 6% Sodium carbonate, 0.0185% formaldehyde and 16 µM sodium thio-
sulphate in ddH2O. 
Solutions for MALDI-Time of flight mass spectrometry (MALDI-ToF MS): 
Elution buffer for IP: 10% Formic acid (FA) in ultrapure ddH2O. 
Sinapinic Acid (SA) matrix: 10 mg/ml of SA in 50% acetonitrile, 50% proteomics grade water 
and 0.1% trifluoroacetic acid (TFA). 
α-Cyano-4-hydroxycinnamic acid (HCCA) matrix: 10 mg/ml of HCCA in 70% acetonitrile, 
30% proteomics grade water and 0.2% TFA. 
Dihydroxybenzoic acid (DHB) matrix: 15 mg/ml of DHB in 90% acetonitrile, 10% proteomics 
grade water and 0.1% TFA. 
Solutions for Protein Digestion: 
Trypsin solution: 12.5 ng/µl Trypsin in 50 mM ammonium bicarbonate. 
Solutions for fibril purification: 
Solution A: 10 mM Tris-HCl (pH 7.4), 0.25 M sucrose, 3 mM EDTA, one protease Inhibitor 
tablet per 50 ml and 0.1% sodium azide. 
Solution B: 10 mM Tris-HCl (pH 7.4), 1.9 M sucrose, 3 mM EDTA, one protease inhibitor 
tablet per 50 ml and 0.1% sodium azide.  
Solution C: 50 mM Tris buffer (pH 8.0) 
Solution D: 50 mM Tris buffer (pH 8.0) and 2 mM calcium chloride. 
Solution E: 50 mM Tris buffer (pH 8.0), 1.3 M sucrose and 1% SDS. 
Real-time quaking-induced conversion (RT-QuIC) seeding Buffer: 7.5 mM Sodium phosphate 
dibasic and 2.5 mM sodium phosphate monobasic (pH 7.4). 
  




2.2 Methods  
2.2.1  Ethics statement  
All sAD, rpAD and control brain samples were obtained from the Institute of Neuropathology 
brain bank, Barcelona, Spain (HUB-ICO-IDIBELL Biobank), according to Spanish legislation 
(Ley de la Investigación Biomédica 2013 and Real DecretoBiobancos, 2014) following informed 
consent of participants or their legal next of kin and the approval of the local ethics committee. 
Sporadic CJD samples were provided by the Department of Neuropathology, University Medical 
Center, Hamburg, Germany. CSF samples, sAD, rpAD and controls were provided by the Depart-
ment of Neurology, University Medical Center, Göttingen, following informed consent of the pa-
tients or their guardians. The study was approved by the local ethics committee in Göttingen (No. 
24/8/12). 
2.2.2  Collection of brain samples 
Frontal cortex samples were obtained from 15 sAD (mean age of 76.8 ± 2.5 years), 8 rpAD (79.8 
± 2.72 years), 8 non-demented control (71.9 ± 2.84 years) and 4 sporadic Creutzfeldt–Jakob dis-
ease (sCJD) brains (74.0 ± 4.0 years). Tissue sections (1 cm thick) from one hemisphere were 
snap-frozen for molecular analysis and stored in -80°C until use. The second hemisphere was used 
for neuropathological assessment to validate the clinical diagnosis. All sAD cases met the Consor-
tium to Establish a Registry for Alzheimer’s Disease (CERAD) criteria for the diagnosis of the 
disease. The rpAD samples were selected according to the current definitions of rpAD (Schmidt 
et al., 2010). Samples with comorbid pathologies that may contribute towards rapid decline and 
those with a family history of AD were excluded from the rpAD cohort. The non-demented con-
trols were chosen such that they had no underlying pathologies that may contribute towards neu-
rodegeneration. For all sAD, rpAD and control cases, Aβ pathology was scored based on the 
CERAD scoring system, while the Braak and Braak staging system was used to score NFTs (Bo-
luda et al., 2014; Braak and Braak, 1991). sCJD cases were diagnosed and selected according to 
current criteria (Zerr et al., 2009). The sample selection was aimed to ensure that no significant 
differences in postmortem delay were evident among various experimental groups (Figure 32). 
The clinical data for all the brain samples utilized in this study are summarized in Appendix A. 




CSF samples were also selected based on the aforementioned criteria. All samples were collected 
through a lumbar puncture, centrifuged at 2000 times gravity (x g) for 10 minutes (min) at 4°C 
and stored at -80°C until further analysis.  
2.2.3  Protein extraction 
For IP, brain tissue (10% w/v) was homogenized in Tris-Triton lysis buffer. Tissue sections in 
lysis buffer were placed in the tissue lyzer for 15 min at 50 Hertz (Hz) to ensure complete lysis. 
The homogenate was incubated at 4°C overnight. The Tris-soluble fraction was isolated by centri-
fuging the samples at 14,000 revolutions per minute (rpm) for 45 min at 4°C. The resultant pellet 
was resuspended in 70% FA, supplemented with protease inhibitor, by sonication on ice for 10 
min to prepare a 10% w/v homogenate again. The supernatant collected from subsequent centrif-
ugation (14000 rpm, 45 min, 4°C) was saved as FA-soluble fraction.  
For 1D-PAGE experiments, brain tissue (10% w/v) was homogenized in Urea-Thiourea lysis 
buffer using a tissue lyzer, followed by overnight incubation at 4°C. The samples were centrifuged 
(14000 rpm, 45 min, 4°C), and the supernatant was saved at -80°C until use.  
2.2.4  Protein quantification 
Proteins extracted in Tris-Triton and Urea-Thiourea lysis buffers were quantified using Bradford’s 
assay (Bradford et al., 1976). Briefly, bovine serum albumin was serially diluted (0.0 µg/ml to 
1000 µg/ml, 20 µl per tube) mixed with 980 µl of Bradford’s reagent to make a final volume of 
1000 µl. Similarly, Bradford’s reagent was added to 20 µl of the diluted sample (sample and ddH2O 
in a ratio of 1:20). The mixtures were incubated at room temperature for 10 min. The absorbance 
at 595 nm was recorded for each standard and sample in duplicates using the Ultospec 2100 spec-
trophotometer. The quantity of protein in samples was estimated using a standard curve of bovine 
serum albumin dilutions. In the case of FA-soluble fractions, proteins were quantified by measur-
ing absorbance at 280 nm by Nanodrop spectrophotometer.  
2.2.5  Immunoprecipitation  
IP of Aβ was performed by slight modifications in the protocol established by Portelius et al., 
(2015). Dynabeads (1.5 mg/0.5 mg of protein sample) were given two washes with 0.3% CHAPS 
and incubated with 4 µl each of two Aβ antibodies, 4G8 and 6E10, for 30 min at 4°C. Tris-soluble 




fraction, 500 µg, was added directly to the coated beads, while the FA-soluble fraction was neu-
tralized with 5 M sodium hydroxide in 1 M Tris before addition. The mixture was incubated over-
night at 4°C. Subsequently, the beads were washed with 0.3% CHAPS to remove non-specific 
proteins bound to the beads. The samples were then eluted in either rehydration buffer for 2D-
PAGE or 10% FA for top-down mass spectrometry by rotating the beads for 10 min at room tem-
perature. The eluates for top-down mass spectrometry were dried in a Speed Vac (30 min). The 
eluates were stored at -20°C until further processing. 
2.2.6  SDS-PAGE and IB analysis 
2D-PAGE for brain-derived and synthetic Aβ was performed with minor modifications in the pro-
tocol optimized previously (Maler et al., 2007). Briefly, IP eluates were diluted with rehydration 
buffer, and isoelectric focusing was performed with pH 3-10, 7 cm, non-linear immobilized pH 
gradient (IPG) strips using previously described program [30 min/300 V, 30 min/800 V, 1 h/2000 
V gradient and 2000 V (Ʃ15000 volt hours)]. The synthetic peptides, 10 ng of Aβ40 and Aβ42 were 
resuspended in rehydration buffer and loaded onto IPG strips and subjected to the same protocol. 
The strips were equilibrated in equilibration buffer I and II for 8 min each. The second-dimension 
separation was conducted using 4-12% gradient Bis-Tris gels, according to the manufacturer’s 
protocol using ready-made 2-(N-morpholino)ethanesulfonic acid (MES) running buffer (Thermo 
Fisher Scientific, Germany). Proteins were transferred onto 0.20 µm PVDF membranes under 
semi-dry conditions with Tris-glycine transfer buffer without SDS (1 mA/cm2, 45 min). The mem-
branes were boiled in PBS for 3 min (antigen retrieval for Aβ antibodies only) and were blocked 
with 5% milk in PBS-T for 1 hour (hr) and incubated with 6E10 antibody (1:1000) overnight at 
4°C. They were rinsed with PBS-T (four washes) followed by incubation with HRP-conjugated 
secondary anti-mouse antibody (1:10000) for 1 hr at room temperature. The unbound antibody 
was removed by washing the blots with PBS-T again. They were then incubated in ECL solution 
for 1 min. The chemiluminescence signal was detected using an ECL solution and ChemiDoc 
Imaging System. The images were analyzed using Delta 2D software. 
The semi-quantitative analysis of various Aβ-cleaving enzymes was performed using 1D-PAGE 
(Laemmli et al., 1970). Tris-glycine resolving (8%) and stacking (6%) gels were prepared using 
the recipes stated in Table 5. The gels were polymerized at room temperature for 20 min each and 
stored at 4 °C until use. Protein samples (50 µg) were diluted with 4x Laemmli buffer and boiled 




at 95°C for 5 min before being loaded on the gels along with the protein standard (5 µl). The gels 
were run at 100 V at room temperature.  
Table 5: Recipe for gels used for 1D SDS-PAGE. 
 Resolving gel (8%) Stacking Gel (6%) 
ddH2O (ml) 4.2 1.3 
Buffer (ml) 2.08 (Resolving gel buffer) 0.525 (Stacking gel buffer) 
40% Acrylamide (ml; Roti-
phorese Gel 40, Carl Roth) 
1.6 0.42 





Proteins were then transferred onto 0.45 µm PVDF membranes under semidry conditions using 
Tris-glycine transfer buffer (14 V, 60 min). Immunoblotting was performed as described above 
for 2D-PAGE. For reblotting, the membranes were incubated in the reblotting buffer for 20 min, 
followed by four washes with PBS-T (5 min each) before being blocked and incubated with pri-
mary antibody again. All blots were stained with MemCode reversible protein stain according to 
the manufacturer’s instructions and normalized through total protein normalization. The images 
were analyzed using Image Lab software. The presented data were obtained from a minimum of 
three independent experiments for each antibody.   
For dot-blot assays, 2 µl sample was directly pipetted on the nitrocellulose membrane. The mem-
branes were dried for 25 min before being blocked and incubated in the primary antibody. Washing 
and imaging were performed as described above for 2D-PAGE. 
2.2.7  Mass spectrometry 
2.2.7.1 Top-down MALDI-TOF mass spectrometry 
Fresh dilutions of matrices (SA, HCCA and DHB) were prepared for each analysis. IP eluates, 
eluted in 10% FA and dried as described in section 2.2.5, were resuspended in 0.1% TFA and 
mixed with the matrix in a ratio of 1:1. In total, 1.5 µl of this mixture was deposited immediately 




on the MALDI plate and incubated for 20 min at room temperature to ensure complete cocrystal-
lization. The resuspended samples that were not deposited immediately on the MALDI plate were 
stored at -20°C until use and sonicated on ice for 10 min to break any oligomers immediately 
before analysis.  
Spectra were calibrated using peptide standard II before each run and peaks were acquired using 
repiflex MALDI Tissuetyper in a m/z range of 1000 to 6000 using positive linear mode. Five 
measurements were taken for each sample and the average spectrum was generated. Peaks were 
analyzed in FlexAnalysis. The background was subtracted and peaks were smoothed according to 
in-built algorithms. Aβ proteoforms were manually annotated based on m/z values. Proteoforms 
with a deviation of more than 5 Da from theoretical mass were excluded from the analysis. The 
analysis was replicated thrice and only the peptides that were detected in at least two out of three 
independent replicates were included in the report. 
2.2.7.2 Liquid chromatography/electrospray ionization tandem mass  
spectrometry (LC-ESI MS/MS) 
Samples were diluted in Laemmli buffer, boiled for 5 min and allowed to run on 4-12% Bis-Tris 
gradient gels to a length of 1 cm using the manufacturer’s protocol. The gels were washed with 
ddH2O twice (5 min each) and were incubated in Coomassie G-250 for 45 min. They were rinsed 
with ddH2O (twice, 5 min each) again and incubated in the destaining solution overnight. The 
bands were excised and washed with ddH2O followed by reduction with 10 mM DTT, alkylation 
with 55 mM IAA and digestion with trypsin overnight at 37°C. Peptides were extracted by adding 
5% FA and 100% acetonitrile. The supernatant was collected, dried and stored at -20°C until anal-
ysis.   
The peptide mixtures were concentrated on a reversed-phase C18 precolumn and separated on a 
reversed-phase C18 nanoflow chromatography column (self-packed with Reprosil-Pur C18 AQ 3 
µm material) using a linear gradient (5-35% acetonitrile vs. 0.1% FA; 15 min) at a flow rate of 
300 nL/min in an Easy nLC-1000 nanoflow chromatography system. The Q Exactive hybrid quad-
rupole/orbitrap MS system (paired with Excalibur software) was used to analyze the eluates using 
the Top10 method in the data-dependent acquisition mode. Tandem mass spectra were obtained 
using Raw2MSM software. MS/MS spectra were analyzed using Mascot instructed for searching 
Swissprot Homo sapiens reference proteome (revision 10.2018) with a mass tolerance of 10 ppm 




for precursors and 0.05 Da for fragments. Methionine oxidation was regarded as a variable post-
translational modification, whereas cysteine modification was set as a fixed modification. MS/MS-
based identification was validated using Scaffold software. A confidence threshold greater than 
95.0% was used for accepting peptide identifications, while a confidence threshold of 99.0%, 
paired with a minimum of two identified peptides, was employed as a prerequisite for accepting 
protein identification.  
2.2.8  Enzyme-linked immunosorbent assay (ELISA) 
N-terminally and C-terminally truncated proteoforms of Aβ were quantified using Aβx-42 (Bio-
legend, Germany), Aβ1-x (IBL International, Germany) and Aβ1-40 (Biosource, USA) ELISA kits. 
Tris-soluble and FA-soluble fractions were prepared and quantified as per to the manufacturer’s 
instructions. Briefly, samples were homogenized in Tris-Triton buffer (20% w/v) and proteins 
were extracted by spinning the samples at 350,000 x g (20 minutes, 4°C). The supernatant was 
collected, and the pellet was resuspended in 70% FA (10% w/v). The FA-soluble fraction was 
extracted by centrifuging the samples at 350,000 x g again. The fractions were quantified by meas-
uring their absorbance at 280 nm by Nanodrop spectrophotometer. The samples were either ana-
lyzed immediately after extraction or stored at -20°C until use. In case of brain extracts, 100 µg of 
protein sample were diluted and loaded in each well, while all CSF samples were diluted in a ratio 
of 1:4 with the sample diluent provided with the kit for analysis. ELISA was performed as in-
structed by the manufacturer. All samples were quantified in duplicates and the average readings 
were analyzed. 
2.2.9  In vitro seeding assay 
2.2.9.1 Fibril purification 
Amyloid fibrils were extracted using minor modifications in the protocol optimized by Lu et al. 
(2013). Briefly, 85 mg of brain tissue were homogenized in 1.7 ml of buffer A using the Tenbroeck 
tissue grinder and incubated overnight at 4°C. Sucrose was added to the homogenate to raise the 
concentration of sucrose to 1.2 M and the mixture was centrifuged at for 30 min 250,000 x g at 
4°C. The pellet was resuspended in 12 volumes of buffer B and centrifuged for 30 min at 125,000 
x g at 4°C. The top-most solid layer was collected and mixed with 200 µl of buffer C followed by 
centrifugation at 8,000 x g for 15 min to remove sucrose. The pellet was dissolved in Buffer D and 
incubated with DNase I (0.01 mg/ml) at room temperature for 2 hr. The mixture was centrifuged 




at 8,000 x g for 15 min again and the pellet was resuspended in Buffer E followed by another 
centrifugation for 45 min at 200,000 x g at 4°C. The pellet was washed with ultrapure H2O and 
saved at -20°C. Aβ fibrils (10% w/v), corresponding to Tris-soluble fraction, were extracted in 
PBS supplemented with protease and phosphatase inhibitors as described in section 2.2.3. 
2.2.9.2 RT-QuIC 
Purified fibrils were resuspended in 15 µl of RT-QuIC seeding buffer and quantified by Nanodrop 
spectrophotometer. Half of the brain extract (7.5 µl; 2-3 µg/µl) was further diluted with the seeding 
buffer to a final volume of 88 µl and sonicated on ice for 10 min. Alternatively, Aβ extracted in 
PBS (15 µl) was used directly. Synthetic peptides were dissolved in hexafluoroisopropanol, ali-
quoted, dried and stored at -20°C until use. Aβ40 and Aβ42 were diluted in DMSO (50 µM) and 
sonicated for 30 min immediately prior to the reaction and added to diluted brain extract along 
with 2 µl of Thioflavin-T in PBS (Th-T; 1 mM) solution. The final reaction volume of each mixture 
was 100 µl. Multiple technical replicates from each sample were incubated simultaneously in FLU-
Ostar Omega plate reader for 46 hr at an intermittent shaking mode (600 rpm for 1 min after every 
29 min) at 37°C. Fluorescent measurements were recorded every 30 min (excitation 450 nm, emis-
sion 480 nm) and used for analysis.  
2.2.10 Native PAGE  
Native gels (8%) were prepared according to the recipes listed in Table 6. The RT-QuIC product 
(8 µl) was added to an equal volume of 2x sample buffer, thoroughly mixed and loaded directly 
into the wells along with the protein standard (1 µl). The gel was run at 150 V on ice until the 
tracking dye reached the bottom of the gel.  
Table 6: Recipe for resolving and stacking gels used for Native PAGE. 
 Resolving gel (8%) Stacking Gel (6%) 
ddH2O (ml) 4.0 2.6 
Buffer (ml) 2.5 (Resolving gel buffer) 1.0 (Stacking gel buffer) 
40% Acrylamide (ml) 1.0 0.4 
10% Ammonium persulfate (µl) 50.0 20.0 
TEMED (µl) 5.0 5.0 
 




The proteins were visualized using silver staining. The gels were stored in fixative solution over-
night. Subsequently, they were washed with 50% and 30% ethanol solution (20 min each), incu-
bated in sensitization solution (1 min) followed by silver nitrate solution (20 min). The bands were 
visualized by shifting the gel to the developing solution for 5 min. The gel was washed to remove 
any remnant solutions and scanned immediately. 
2.2.11 Confocal laser scanning microscopy 
Th-T dye (1 mM) was added to RT-QuIC products in a ratio of 1:10. The resulting mixture (1 µl) 
was added to glass slides and directly imaged at 488 nm using Zeiss LSM 510 Meta Confocal laser 
scanning microscope. 
2.2.12 Atomic force microscopy 
RT-QuIC products (5 µl) were added to freshly stripped micas and incubated for 20 min at room 
temperature. The coated micas were washed thrice with ultrapure H2O (10 µl) to remove salts and 
other impurities, and excess H2O was removed with a gentle nitrogen stream. The samples were 
imaged in intermittent contact mode (tapping mode) using the MFP-3D Infinity microscope and 
Olympus microcantilevers (OMCL-AC160TS) at a drive frequency of 260.058 kHz, guided by 
Igor Pro software. The scan area for each image was 10 µm2 and the scan rate was 0.5 Hz. 
2.2.13 Fourier-transform infrared spectroscopy (FT-IR)  
Potassium bromide pellets were prepared in a hydraulic press and coated with RT-QuIC products 
(20 µl). The samples were scanned in the range of 400-4000 cm-1 in a Spectrum 100 spectropho-
tometer using Spectrum software and the percentage transmittance was recorded. For each sample, 
spectra recorded for two separate reactions were averaged and used for final analysis.  
2.2.14 Toxicity assays 
2.2.14.1 Preparation of oligomeric and fibrillar fractions 
RT-QuIC products from each target well were diluted with Optimem serum-free medium (Gibco, 
Germany) to a final concentration of 20 µM and centrifuged at 20,000 x g for 10 min to separate 
oligomeric and fibrillar fractions. The pellet was resuspended in 25 µl of the medium, while the 
supernatant was used directly.  




2.2.14.2 Cell treatments and MTS assay  
SH-SY5Y cells (30,000 cells/well) were platted in a 96 well plate in Optimem supplemented with 
1% P/S at 37 °C, 5% CO2. After 24 hr, the medium was replaced with 100 µl Optimem containing 
fractionated extract and incubated for another 24 hr. MTS reagent (10 µl) was added to each well 
and the absorbance at the wavelength of 490 nm was recorded after 3 hr. 
2.2.15 Bioinformatic tools and statistical analysis 
The data were analyzed and visualized using PRISM and RStudio. P-values were determined using 
either one-way ANOVA followed by Tuckey’s post hoc test or unpaired Student’s t-test, and val-
ues ≤ 0.05 were considered significant. All data are expressed as mean ± standard error of the mean 
(SEM), unless stated otherwise. Functional categorization of proteins was performed using Uni-







3.1 Extraction and identification of Aβ proteoforms 
The characterization of Aβ proteoforms is crucial for our understanding of the pathways involved 
in common neurodegenerative pathologies, especially AD and its clinical subtypes. However, the 
low concentrations of targeted proteoforms and their resistance to standard biochemical and mo-
lecular techniques complicates their analysis. Moreover, a majority of studies have focused on 
Aβ40 and Aβ42 only, ignoring the potential role of other proteoforms. This part of the study focused 
on extraction and identification of brain-derived proteoforms from clinical subtypes of AD. Brain 
proteome was divided into two pathologically relevant fractions, namely Tris-soluble and FA-sol-
uble fractions. Tris-soluble fractions comprise of smaller, soluble Aβ species that impart toxic 
effects within the cell body. The FA-soluble fraction, on the other hand, corresponds to insoluble 
Aβ species deposited as fibrils and plaques that sequester circulating Aβ and may function as a 
reservoir. 
3.1.1 Various Aβ proteoforms are present in sAD and rpAD brains 
Aβ-enriched fractions were prepared by IP of proteins extracted from Tris-soluble and FA-soluble 
fractions using antibodies against two domains of the Aβ peptide to ensure the extraction of all 
endogenously cleaved proteoforms. The IP protocol was optimized to reduce the loss of pro-
teoforms captured by the beads during the washes (Figure 6). The elution buffers were selected to 
minimize fibrillization of Aβ and maintain extracted Aβ proteoforms as monomeric species for 
further analysis by modulating the amount of urea (8.3%) or FA (10%).   
2D-PAGE, followed by IB analysis with either 6E10 and 4G8 antibody, was used to validate the 
presence of various Aβ proteoforms in IP eluates before further analysis. Although an overall sig-
nature of total Aβ was visualized by 6E10 and 4G8 antibodies, the expression of specific pro-
teoforms could not be tested due to the lack of proteoform-specific antibodies. Therefore, a virtual 
2D map of common Aβ proteoforms, in their monomeric form, presented in Figure 7A, was used 
to annotate various spots, in addition to the 2D-PAGE analysis conducted for synthetic pro-







Figure 6: Coomassie-stained gel of IP washes validates the efficiency of IP protocol. IP washes 
(W1-W4) from two different samples were run on a 12% Tris-Glycine gels and stained to ensure 
that protein loss was kept to a minimum during IP protocol. Absence of the typical bands of Aβ, 
usually visualized at 20 kilodaltons (kDa), 24 kDa and 56 kDa in 1D-PAGE, indicated no loss of 
Aβ proteoforms bound to beads.  
 
Figure 7: Virtual 2D-PAGE map of common Aβ proteoforms and IB analysis of synthetic 
peptides. (A) Virtual 2D map of common Aβ proteoforms showing different locations of various 
C-terminally truncated (orange), N-terminally truncated (blue) and both C and N-terminally trun-





indicate few proteoforms from our dataset. The immunoblot image for synthetic (B) Aβ42 and (C) 
Aβ40 is also presented. 
In all tested samples, the molecular weight-based pattern of Aβ monomers and oligomers obtained 
was in accordance with previous reports for 1D-PAGE and major spots were obtained at 4 kDa, 
20 kDa, 24 kDa and 56 kDa, corresponding to monomers, pentamers, hexamers and dodecamers 
respectively (Figure 8). A similar signature was also obtained by IB using the 4G8 antibody. The 
pI-based resolution presented the major spots for various N-terminally and C-terminally truncated 
monomeric Aβ at 4.89, 5.31, 5.76 and 6.27. The presence of spots at pI other than 5.31 validated 
the presence of proteoforms other than Aβ40 and Aβ42 in sAD and rpAD brains and confirmed the 
efficiency of the IP protocol. 
 
Figure 8: Representative blots for expression of monomeric and oligomeric Aβ proteoforms 
in sAD, rpAD and control brains. 2D IB, with 6E10 antibody, indicated various N-terminally 
and C-terminally truncated Aβ proteoforms as monomers, pentamers, hexamers and dodecamers 
in Tris-soluble and FA-soluble fractions isolated from the brain. Each membrane represents one 
sample. T-fraction stands for the Tris-soluble fraction. 
3.1.2 Aβ-proteoform signature is different in sAD and rpAD 
The spots on membranes from all experimental groups were matched using Delta2D software by 
100% spot matching approach (Figure 9). Although both Tris-soluble and FA-soluble fractions 
from sAD and rpAD cases as well as controls were tested, the sensitivity of Western blot allowed 
the detection of monomeric proteoforms in FA fractions from sAD and rpAD brains only. All 





including Aβ40, Aβ42, Aβ38), 5.76 (presenting shorter C-terminally truncated proteoforms including 
Aβ20, Aβ18, Aβ16) and 6.27 (showing N-terminally truncated proteoforms including Aβ4-42). An 
additional spot was detected at pI of 4.89 in one sAD case, that indicates the presence of interme-
diate C-terminally truncated proteoforms including Aβ26. In rpAD cases, on the other hand, the 
two major spots detected were at pI of 5.31 and 6.27 and only one case showed a faint spot at 5.71.  
 
Figure 9: Delta 2D visualized the presence of differentially expressed Aβ proteoforms in sAD, 
rpAD and control cases. (A) 2D Western blot indicated differential expression of monomeric and 
oligomeric Aβ proteoforms in sAD, rpAD and control brains. (B) Arrowheads indicate the differ-
entially expressed proteoforms among sAD and rpAD cases. Each membrane represents one sam-
ple. A total of five replicates per group were tested for Aβ proteoforms. T-fraction stands for the 
Tris-soluble fraction. 
It is noteworthy that, in all rpAD cases, Aβ was concentrated in 56 kDa and 24 kDa range and 
fewer spots were present at 4 kDa region, portraying a higher propensity of Aβ from rpAD brains 
to aggregate in response to SDS in gels (Figure 9). Conversely, sAD cases showed greater variety 





3.1.3 Aβ40, Aβ42, Aβ4-42, Aβ11-42 and their pyroglutamate counterparts are 
the primary proteoforms in FA-soluble fractions of sAD and rpAD 
brains 
The lack of proteoform-specific antibodies limited the utility of IB analysis for this study therefore, 
the identification of proteoforms was conducted using various mass spectrometric tools. The first 
method of choice was LC-ESI MS and spots from Coomassie-stained gels were extracted, digested 
and subjected to identification via a bottom-up approach. The presence of Aβ was verified in tar-
geted spots, however, tryptic digestion created inference problems by cleaving proteoforms further 
and masking the endogenous signature (Figure 10A). The top-down approach was then utilized to 
identify Aβ and dried IP eluates, resuspended in a mixture of FA, isopropanol and ddH2O (4:4:1), 
which were directly injected in the column for identification. Peaks for Aβ3-42, Aβ40 and Aβ42 were 
identified through this strategy (Figure 10B). Upon replication, this method gave highly non-re-
producible findings and the multiply ionized species, characteristic of electrospray ionization 
method, complicated downstream analysis of identified proteoforms.  
Top-down MALDI-ToF MS was next tested for its capability to resolve the signature of endoge-
nous Aβ proteoforms. The dried IP eluates were resuspended in 0.1% TFA and directly spotted on 
the MALDI plate. Initially, three matrices, namely SA, HCCA, and DHB, known for an efficient 
ionization of peptides and small proteins were used for ionization. The signal-to-noise ratio (S/N) 
and the qualities of peaks for all matrices were compared. Using this approach, SA was selected 
for further analysis based on best resolution, highest S/N ratio, reproducibility and analyzable 
quality of peaks (Figure 11).  
As predicted by Western blot data from 2D-PAGE, identifiable peaks of monomeric Aβ pro-
teoforms were detected only in FA-soluble fractions from sAD and rpAD brains. Aβ40 was detected 
in FA-soluble fractions of some control cases, however these cases were excluded from the anal-
ysis as the quality of peaks was poor, resulting in non-reproducible findings. The Tris-soluble 
fractions presented a pattern similar to the negative controls, indicating that the amount of Aβ was 
below the detection limit (Figure 11). 
Initial experiments identified 38 differentially cleaved Aβ proteoforms through top-down mass 





pendent experiments were included in the final dataset (Appendix B). Of the 33 proteoforms se-
lected for analysis in sAD and rpAD brains by MALDI-ToF MS, Aβ40, Aβ42, Aβ4-42, Aβ11-42,  py-
roglutamate Aβ3-42 (Aβp3-42) and pyroglutamate Aβ11-42 (Aβp11-42) were common to both sAD and 
rpAD cases. Aβ42 and Aβ4-42 were most abundant proteoforms in all cases studied. Aβ1-12, Aβ2-14, 
Aβ3-14, Aβ15-38 and Aβ4-40 were found to be more common in sAD cases, whereas Aβ5-27 and Aβ9-
40 were more common in rpAD cases. A heatmap depicting the relative amounts of various pro-
teoforms extracted from individual cases is presented in Figure 12. Experimentally induced mod-
ifications were avoided by omitting tryptic digestion, however a 16 Da modification was observed 
for some proteoforms due to FA treatment. 
 
Figure 10: Strategy for identification of Aβ proteoforms through LC-ESI MS. Proteoform 
signature of Aβ was identified by subjecting either stained gel spots or IP eluates to LC-ESI-MS. 
(A) The gel-based, bottom-up approach validated the presence of Aβ presented as the extracted 
ion chromatogram and sequence identified with 100% probability. (B) Peaks for multiply charged 






Figure 11: Representative spectra obtained from various fractions isolated from sAD, rpAD 
and control brains in various matrices. Spectra obtained from various samples in (A) HCCA 
and (B) DHB overlapped with the spectrum of negative controls and gave very low S/N ratio. On 
the other hand, samples ionized with SA, especially (C) sAD and (D) rpAD were resolved with 
high S/N ratio, thus SA was selected for further analysis. Peaks for singly charged Aβ1-38, Aβ2-42, 
Aβ4-42, Aβ5-42, Aβ40 and Aβ42 can be observed in both spectra. However, the concentrations of pro-
teoforms in FA-soluble controls (E) and Tris-soluble fractions for all groups (F) were below the 






Figure 12: Diversity in proteoforms identified in FA-soluble fraction from sAD and rpAD 
brains. Top-down MALDI-ToF MS identified 33 different proteoforms of Aβ. Although inter-
subject variability is evident in proteoform signature obtained from various cases, Aβp11-42, Aβ11-
42, Aβ4-42, Aβ1-40 and Aβ1-42 are the most dominant proteoforms. The heatmap depicts the relative 
intensities of all identified proteoforms, calculated using the average area under the curve (AUC) 
from five measurements taken for each sample. The intensities were normalized for each sample 
and the respective Z-scores of proteoforms were used for this plot. pAβ represents pyroglutamate 
Aβ proteoforms.  
3.1.4 No differences are evident in the quantity of APP and Aβ pro-
teoforms in sAD and rpAD 
The relative expression of APP affects the downstream generation of Aβ proteoforms. The amount 
of APP was thus quantified in controls, as well as in sAD and rpAD cases by performing densito-
metric analysis of 100 kDa band visualized in IB analysis with 6E10 antibody in the Tris-soluble 
fraction of brain proteins. However, no differences were evident among the three groups. The 
amount of AβTotal was also tested in these samples and the 4 kDa band for monomeric Aβ was only 
visualized in FA-soluble fractions of sAD and rpAD cases, as predicted by 2D-IB and MALDI-
ToF MS. Although rpAD appeared to have higher expression of AβTotal, the differences among the 






Figure 13: Relative expression of APP and  AβTotal in sAD and rpAD cases. The expression of 
APP and AβTotal was quantified using IB analysis with 6E10 antibody (n = 5). Tris-soluble fractions 
were loaded directly, whereas the FA-soluble fractions were dried, resuspended in Laemmli buffer 
and sonicated for 10 min before being loaded. APP was only present in Tris-soluble fractions and 
AβTotal was present in FA-soluble fraction only. No significant differences were visualized in either 
IB when tested with one-way ANOVA. All blots were subjected to total protein normalization, 
and data from three independent experiments were used for densitometric analysis. Error bars rep-
resent SEM. 
Western blot analysis did not detect Aβ in control cases and the proteoform-specific signature also 
could not be tested due to the lack of specific antibodies. Therefore, ELISA was performed to test 
the relative quantities of C-terminally truncated Aβ proteoforms in controls, sAD and rpAD brains. 
Their quantity was significantly higher in FA-soluble fraction of sAD and rpAD cases in compar-
ison to controls. However, no such trend was evident in the Tris-soluble fraction (Figure 14A). 
Similarly, results from ELISA measurements for N-terminally truncated proteoforms also showed 
the highest amounts in the FA-soluble fraction of sAD, followed by rpAD and controls, however, 
the differences were not significant. Likewise, there were no significant differences among the 






Figure 14: Relative expression of N-terminally and C-terminally truncated proteoforms of 
Aβ in brain samples. The graph presents the quantities (pg/µg of total brain protein) of various 
(A) C-terminally and (B) N-terminally truncated proteoforms isolated from Tris-soluble and FA-
soluble fractions from controls, sAD and rpAD cases (n = 4-6). (C) Comparison of various trun-
cations within the Tris-soluble fractions. (D) The relative quantity of Aβ1-40 in various experi-
mental groups. All samples were measured as duplicates and the average concentrations were used 
for analysis. One-way ANOVA, followed by Tukey’s multiple comparisons test, was used for 
statistical analysis. Error bars represent SEM. (*=p≤0.05; **= p≤0.01; ***= p≤0.001) 
In Tris-soluble fractions, ELISA results showed a lower amount of C-terminally truncated pro-
teoforms in comparison to N-terminal truncations in all control, sAD and rpAD cases. This trend 
was especially evident in sAD cases, where the amount of N-terminally truncated Aβ was signifi-
cantly higher than its C-terminal counterparts, possibly because shorter proteoforms are less prone 
to aggregation and are frequently formed during the clearance of highly aggregated, larger pro-
teoforms (Figure 14C). The FA-soluble fractions showed no significant differences among N-ter-
minally and C-terminally truncated pools. Additionally, Aβ40 was only present in detectable 
amounts in Tris-soluble fraction and its quantity was significantly higher in sAD and rpAD cases 





CSF from sAD, rpAD and control cases was also tested for N-terminal and C-terminal truncations. 
Although the amount of C-terminally truncated proteoforms was significantly higher (p ≤ 0.0001) 
in all three study groups than their N-terminally truncated counterparts, no significant trend was 
evident within groups for either ELISA test (Figure 15). 
 
Figure 15: Relative expression of N-terminally and C-terminally truncated proteoforms of 
Aβ in CSF samples. No significant differences were observed among experimental groups for 
either ELISA test, but the amount of C-terminally truncated proteoforms was significantly higher 
than N-terminally truncated proteoforms in all three study groups (n = 6). All samples were meas-
ured as duplicates and the average concentrations were used for analysis. One-way ANOVA, fol-
lowed by Tukey’s multiple comparisons test, was used for statistical analysis. Error bars represent 
SEM. (****= p≤0.001). 
3.1.5 The expression of β-secretase, relative to α-secretase, is significantly 
higher in rpAD 
The slight differences in the signature of proteoforms among sAD and rpAD cases called for the 
quantification of Aβ-cleaving enzymes. Western blot analysis was performed for enzymes that 
take part in the generation and clearance of Aβ, including α-secretase (ADAM-10), β-secretase 
(BACE-1), γ-secretase (PSEN-1, PSEN-2 and Nicastrin), plasmin and IDE. Owing to the alteration 
in the expression of enzymes in various stages of the disease, sAD cases were divided into two 
groups corresponding to Braak stages I-III (early sAD) and Braak stages IV-VI (late sAD). How-
ever, no significant differences were observed in their expression levels among controls, sAD and 






Figure 16: Western blot analysis for the relative expression of major Aβ-cleaving enzymes. 
The relative expression of α-secretase, β-secretase, γ-secretase, plasmin and IDE in non-demented 
controls, early sAD (Braak stages I-III), late sAD (Braak stages IV-VI) and rpAD cases demon-
strated no significant differences (n = 6). All blots were subjected to total protein normalization. 
Densitometric analysis was conducted using data from three independent experiments. One-way 
ANOVA, followed by Tukey’s multiple comparisons test, was used for statistical analysis. Error 
bars represent SEM. 
Interestingly, the expression of BACE1, our targeted β-secretase, relative to ADAM-10, was sig-
nificantly higher in rpAD in comparison to other groups, indicating increased cleavage of Aβ 






Figure 17: Ratio of BACE-1/ADAM-10 in typical and rapidly progressive AD. The graph de-
picts the expression of BACE-1 in relation to ADAM-10 in non-demented controls, early sAD 
(Braak stages I-III), late sAD (Braak stages IV-VI), and rpAD cases (n = 6). One-way ANOVA, 
followed by Tukey’s multiple comparisons test, was used for statistical analysis. Error bars repre-
sent SEM. (* = p≤0.05). 
3.2 Structural heterogeneity in fibrils extracted from sAD and rpAD brains 
Structural alterations in fibrillar aggregates formed by Aβ proteoforms are another source of vari-
ability in the Aβ-induced toxic effects and are frequently used as an explanation of heterogeneity 
in the clinical presentation of AD cases. Slight alterations in structure translate to modified bio-
chemical properties, incubation periods, propagation and toxicities. As our IB and ELISA experi-
ments detected no significant differences in the quantities of Aβ proteoforms in section 3.1.4, it 
was proposed that the differences in the clinical presentation may lie in the attributes of fibrils 
rather than their quantities. Hence, this part of the project focused on establishing if fibrils ex-
tracted from sAD and rpAD cases have differences in aggregation kinetics, secondary structure 
and 3D morphologies.  
The study of structural differences within endogenously generated fibrils requires mild purification 
protocols where tissue homogenization methodology and extraction agents do not damage and 
alter the specific 3D morphology of fibrils. Consequently, the total amount of extracted fibrils is 
reduced, and large amounts of brain tissue are required for biophysical studies. To overcome these 
challenges, Aβ fibrils were extracted by slight alterations in previously optimized protocols fea-
turing homogenization of brain tissue by mild methodology using differential ultracentrifugation 
(Lu et al., 2013). The presence of fibrils in the extracted fractions was confirmed by Th-T staining 





QuIC reactions. RT-QuIC ensures that the structural characteristics of fibrils are copied onto sub-
strate proteoforms added in the reaction. The total amount of brain tissue utilized was thus reduced 
and analyzable quantities of fibrils were obtained. As reported in section 3.1.3 of this study, Aβ40 
and Aβ42 are some of the most common proteoforms reported in aggregates in both sAD and rpAD 
patients. Therefore, synthetic Aβ40 and Aβ42 were used as a substrate for RT-QuIC reactions. 
 
Figure 18: Thioflavin-T-stained images of Aβ fibrils extracted from sAD and rpAD brains. 
Fibrils purified via ultracentrifugation were mixed with Th-T (10:1) and imaged using confocal 
microscopy to validate the efficiency of our purification protocol. The image shows fibrils visual-
ized in sAD and rpAD samples. The number of fibrils in control samples was too low, therefore, 
an image for that experimental group is not included. Scale bar represents 100 µm.  
3.2.1 Brain-derived Aβ fibrils from sAD and rpAD cases feature different 
aggregation kinetics  
Fibrils extracted from all experimental groups were amplified and their subsequent RT-QuIC pro-
files were utilized to establish differences in their aggregation kinetics. Unlike other amyloido-
genic proteins, where the aggregating seed is only present in cases with the disease, fibrillar Aβ is 
also present in healthy controls, and the substrate itself (especially longer proteoforms including 
Aβ40 and Aβ42) has a high propensity to self-aggregate. Hence, the efforts to optimize the protocol 
were initially targeted to ensure that samples without any seed (substrate-only controls) undergo 
minimal aggregation. The signal obtained for unseeded reaction was negligible in comparison to 
their seeded counterparts. The samples without any substrates (seed-only controls) were also not 
positive for RT-QuIC (Figure 19). A similar trend was also observed in non-demented controls, 
where the signal showed no increase throughout the reaction, showing that Aβ proteoforms in these 
cases were probably not enough to seed the conversion under our reaction conditions (Figure 19B). 





signal in this experiment. Interestingly, the conversion of monomeric substrate to its fibrillar, β-
sheet-rich counterpart was faster in sAD cases in comparison to rpAD, as indicated by kinetic 
curves in Figure 19C. However, seeds corresponding to Tris-soluble fraction showed no such trend 
(Figure 19D). 
 
Figure 19: Kinetic curves obtained for Aβ RT-QuIC reactions seeded with the fibrillar ex-
tract from sAD, rpAD, and controls. (A) The graph was plotted using an average of four meas-
urements recorded for each of three biological replicates in every experimental group in two inde-
pendent experiments. One reading was recorded every 30 min for 46 hr. No seeding was observed 
in seed-only and substrate-only controls. (B) Non-demented controls depicted higher absorbance 
in comparison seed-only and substrate-only controls, however, no increase was recorded in the 
signal throughout the experiments, indicating that no seeding occurred in this group. (C) Only the 
rpAD and sAD showed an increase in Th-T signal and seeding occurred faster in sAD cases. (D) 
Seeds extracted in PBS (corresponding to Tris-soluble fraction) failed to undergo aggregation un-
der these reaction conditions. Error bars represent SEM. 
The trend observed in RT-QuIC profiles was further verified by running the products on native-
PAGE (Figure 20). Two major bands (around 28 kDa and 250 kDa) were detected by silver stain-
ing. Their intensity was higher in rpAD and sAD cases (250 kDa band had higher intensity than 
28 kDa band) in comparison to other groups, suggesting more efficient conversion of substrate 
into aggregates. Faint bands were present in non-demented and seed-only controls, however, the 





of the reaction mixture in their original confirmation or that the control cases might be aggregating 
very slowly. Importantly, no higher-order aggregates (250 kDa and higher) were detectable in 
substrate-only controls, demonstrating that conversion was only positive in the presence of seed.  
 
Figure 20: Native gels for verification of Aβ aggregation in RT-QuIC reaction. RT-QuIC 
products were resolved on native gels and the bands were visualized using silver staining. The 
intensity of higher-order aggregates (> 250 kDa) was higher in sAD and rpAD cases than non-
demented controls, while they were completely absent in substrate-only controls ruling out the 
self-aggregation of the substrate. 
Although the ELISA and IB results in section 3.1.4 showed that the amount of various Aβ pro-
teoforms was not significantly different in sAD and rpAD cases, additional dot-blot assays were 
employed to characterize the RT-QuIC reaction mixtures and ensure that the differences in aggre-
gation kinetics are attributed to the biochemical nature of the seeds, not their quantity. No signifi-
cant differences were observed in both the concentration of Aβ in the reaction mixture and Th-T 
absorbance of purified fibrils before RT-QuIC analysis, thereby confirming the existence of dif-







Figure 21: Characterization of RT-QuIC reaction mixtures. (A) The total amount of Aβ in RT-
QuIC reaction mixtures was assessed via dot-blot assays with 6E10 antibody. No significant dif-
ferences were evident in the relative absorbance. Data from three independent experiments were 
used for analysis. (B) Th-T absorbance, another parameter to analyze the total amount of amyloids 
in the mixture, also demonstrated no significant differences in fibrillar Aβ among sAD and rpAD 
cases. One-way ANOVA, followed by Tukey’s multiple comparisons test, was used for statistical 
analysis. Error bars represent SEM. 
3.2.2 Aβ aggregates from clinical subtypes of AD vary in size and mor-
phology  
Differences in Aβ aggregates seeded using extracts from sAD, rpAD and control brains were vis-
ualized using confocal and atomic force microscopy. The RT-QuIC reactions seeded with rpAD 
brain extracts yielded significantly larger aggregates in comparison to aggregates generated by 
sAD and non-demented controls, despite their slower rates of aggregation observed in section 





cantly different from controls (Figure 22). Smaller aggregates were also present in seed and sub-
strate-only, however, the fact that that no increase in Th-T signal was observed during their gen-
eration indicated that these structures did not change during the reaction. Moreover, their fre-
quency was too low for analysis, so these samples were not included in the graph.  
 
Figure 22: Differences in sizes of aggregates from sAD and rpAD visualized by Th-T staining 
and confocal microscopy. RT-QuIC products from each well were mixed with Th-T (1:10), de-
posited on glass slides and imaged immediately using 488 nm filter. The size of the aggregates 
was calculated by measuring the average size of 40-50 structures per experimental group. The 
aggregates from rpAD were significantly larger than those observed for controls and sAD. One-
way ANOVA, followed by Tukey’s multiple comparisons test, was used for statistical analysis. 
Scale bar represents 250 µm and error bars present SEM (**= p≤0.01; ****= p≤0.0001). 
Although confocal microscopy was useful to calculate the average size of aggregates, its resolution 
was not sufficient to visualize alterations in the 3D structure of individual fibrils. Therefore, atomic 
force microscopy was performed on RT-QuIC products. As expected, a similar trend was observed 
for the three experimental groups. rpAD samples featured large amorphous structures, whereas 
sAD cases presented smaller aggregates with well-defined fibrils. The amorphous structures ob-
served for rpAD may be products of highly hydrophobic fibrils that have higher propensity to bind 





globular structures suggesting that these cases did not seed the aggregation of the substrate (Figure 
23).  
 
Figure 23: Representative amplitude images obtained for RT-QuIC products via tapping 
mode atomic force microscopy. Samples were coated on freshly cleaved mica and imaged im-
mediately. Control cases presented globular seeds-only, whereas sAD and rpAD cases showed 
fibrillar and amorphous aggregates respectively. Zoomed in figures present the detailed structure 
of fibrils. Scale bar represents 1 µm and 200 nm. 
The average thickness of fibrils obtained from sAD and rpAD samples was calculated to further 
validate the differences in 3D folding of Aβ. The fibrillar structures observed in sAD seeded reac-
tions had significantly lesser thickness in comparison to those seeded by rpAD extract. Im-





were buried inside the structure, were ignored to avoid bias in data (Figure 24A). The maximum 
height of aggregates observed was also higher for rpAD cases in comparison to sAD cases (Figure 
24B and C). Since no distinct fibrils were visible in control cases, their measurements were not 
included in the data set. The globular aggregates they formed had an average diameter of 200 ± 
16.6 nm and might just present seeds that failed to undergo any aggregation.  
 
Figure 24: Differences in fibrils and aggregates seeded with sAD and rpAD brain extract. All 
atomic force microscopy data was levelled by three-point levelling tool and heights of individual 
fibrils and larger aggregates were measured using 2-3 height retrace images per sample. (A) rpAD 
cases featured thicker fibrils in comparison to sAD cases. Consequently, the maximum height of 
aggregates observed for sAD cases (B) was much lower than that observed for rpAD cases (C), as 
seen in the 3D height profiles. Statistical analysis was performed using unpaired Student’s T-test. 
Error bars represent SEM. (****= p≤0.001). 
3.2.3  FTIR spectroscopy detected no differences within secondary struc-
tures in Aβ aggregates 
The stability of amyloid fibrils relies on their secondary structures. FTIR spectroscopy was used 
to study the amide I, II and III bands, located at 1645, 1551 and 1230 cm-1 of the infrared spectrum, 
respectively, and to analyze differences in the secondary structures of fibrils generated by sAD 
and rpAD samples in RT-QuIC reactions. The amide I band is especially useful in predicting the 
percentage of α-helices and β-sheets within amyloid fibrils. However, no differences were detected 





from these experimental groups were highly similar. A greater intensity of peaks for sAD cases 
within the Amide I region, reflects a higher concentration of ordered fibrils, in comparison to 
rpAD. Interestingly, control cases also presented a similar spectrum depicting that the secondary 
structure of misfolded seeds within these samples was also similar to the one translated onto grow-
ing fibrils (Figure 25).  
 
Figure 25: Difference in secondary structures of RT-QuIC products seeded by brain extracts 
from different experimental groups. FTIR spectroscopy detected no shifts in peaks obtained for 
different amide bands from sAD and rpAD cases indicating similarities in secondary structures. 
The peaks from control samples also resided around the same range of wave lengths, while a de-
crease in their absorbance reflected a lower amount of targeted functional groups. Substrate-only 
controls were included to show the background absorbance in the absence of any seed in the reac-
tion. The figure presents the average absorbance recorded from products obtained from two inde-
pendent experiments for each sample. 
3.3 sAD- and rpAD-derived Aβ fibrils have similar toxicities 
The toxicities of Aβ proteoforms and their respective fibrillar aggregates rely on their ability to 
interact with various cellular components and organic molecules. Owing to the heterogeneity in 
the types of structures obtained by RT-QuIC, the samples were centrifuged before their application 
on the cells. Two fractions, oligomeric and plaque-associated fibrils were obtained and applied to 
cells separately. It is noteworthy that the plaque-associated fraction showed little to no protein 
content, suggesting that the sizes of fibrils obtained from each experimental group qualified to be 





with plaque-associated fibrils from control, sAD and rpAD seeded reactions. Fibrils obtained from 
sAD and rpAD fractions were more toxic to the cells than the control group, however, the differ-
ences within these two groups were not significant (Figure 26). 
 
Figure 26: Relative toxicities of sAD- and rpAD-derived fibrils in SH-SY5Y cells. Cells were 
treated with RT-QuIC products for 24 hr and the toxicity was measured using MTS assay. The 
survival of samples, relative to vehicle-exposed cells, treated with the oligomeric fraction from 
sAD and rpAD cases showed higher toxicity compared to cells treated with plaque-associated 
fractions, however, the differences within these groups were not significant. The plaque associated 
fractions showed no differences in toxicity. Data from three independent experiments were utilized 
for this plot. One-way ANOVA, followed by Tukey’s multiple comparisons test, was used for 
statistical analysis. 
3.4 sAD and rpAD present a distinct signature of Aβ-interactors and acces-
sory proteins 
All protein-forming complexes with Aβ isolated from sAD, rpAD and control brains were identi-
fied using co-IP followed by LC-ESI MS/MS. CJD was added as another experimental group to 
this experimental set-up to test for similarities in Aβ interactors extracted from brains of rpAD and 
CJD patients. Although Aβ pathology is not the primary driving force behind CJD, Aβ plaques 





detected in this dataset, however, after removing the common contaminants and the proteins that 
were reported in negative controls, 41 interactors were filtered. Only the proteins that were re-
ported in at least two out of four biological replicates for each experimental group with a spectrum 
count of more than 2 and a confidence threshold of 99.0% were included in the final dataset. The 
disease-specific distribution of Aβ interactors is summarized in Figure 27 while the detailed char-
acteristics of identified interactors are presented in Table 7.  
 
Figure 27: Disease-specific distribution of Aβ interactors isolated from Tris-soluble fractions 
of brain tissue obtained from controls, sAD, rpAD, and CJD. The signature of Aβ interacting 
partners was obtained by identifying the proteins purified through co-IP (n = 4). The figure depicts 
the disease-specific distribution of these interacting partners.  
However, several key interactors of the target peptide, like tau and PrPC, were missing in the da-
taset from the Tris-soluble fractions. In an attempt to get an insight into potential binding partners 
of remaining Aβ in the FA-soluble fraction, a similar co-IP was performed. However, solubiliza-
tion and extraction of proteins in FA breaks all the intrinsic interactions and all the interacting 
partners detected by LC-ESI MS/MS for this fraction are a result of in vitro interactions between 
Aβ and neutralized proteins (proteins undergo partial refolding upon neutralization) formed during 
overnight incubation. CJD cases were not included in this experiment as they did not present any 
promising differences in the IP experiment conducted on Tris-soluble fraction. The disease-spe-
cific signature of these in vitro interactors is shown in Figure 28. Since the interactions were not 
limited by compartmentalization of proteins, as is the case of in vivo interactions, a total of 614 
proteins were detected in this dataset, however, after removing the common contaminants and the 
proteins that were detected in negative controls, 340 interactors were finalized. The specificity, 





Table 7: Aβ interactors isolated from Tris-soluble fractions of controls, sAD, rpAD and CJD. 
The list of Aβ-interacting partners obtained through co-IP, along with their localization, function 
and distribution, is summarized (n = 4). The localization and biological functions of identified Aβ 
interactors were annotated using the UniProtKB database. ‘A’ stands or sAD, ‘R’ for rpAD, ‘C’ 
for controls, ‘Mit’ for mitochondria, ‘Nu’ for nucleus, ‘Cy’ for cytoplasm, ‘Cysk’ for cytoskeleton, 
‘Mem’ for cell membrane and ‘ER’ for endoplasmic reticulum. 
Identified Proteins UniProt ID Localization Functional Category Specificity 
ATP synthase subunit beta  P06576 Mit Energy metabolism C, R. 
40S/60S ribosomal proteins  P62277 Nu Translation C, CJD, R. 
Actin-related protein 2, 3 P61160 Nu, Cysk Cysk organization/Axon 
growth 
C, R. 
Adenosylhomocysteinase 2  O43865 ER Translation C. 
Adenylate kinase isoenzyme  P00568 Cy  Energy metabolism R. 
ADP/ATP translocase 1, 2 P12235 Mit Energy metabolism C, R. 
AP-2 complex subunit beta  P63010 Mem Transport, Recycling of 
synaptic vesicles 
CJD. 
Band 4.1-like protein 3  Q9Y2J2 Mem, Cysk Apoptosis, Cysk organi-
zation 
C. 
Citrate synthase O75390 Mit Glucose metabolism  C, R, A. 
Cleavage and polyadenylation 
specificity factor 
O43809 Nu mRNA processing R. 
Cysteine-rich protein 2  P52943 Cy Cell division C. 
Dihydropteridine reductase  P09417 Mit, Cy Redox homeostasis R, A. 
Dihydropyrimidinase-related 
protein 2  
Q16555 Cy Axon guidance  R, C. 
Fructose-bisphosphate aldolase 
C  




tein-like 2  
P60520 Golgi  Transport C, CJD, R. 
GTPase KRas  P01116 Cy Signal transduction C, R. 
GTP-binding nuclear protein 
Ran  
P62826 Nu, Cy Transport All. 
Immunoglobulin superfamily 
member 8  
Q969P0 Mem Neurite outgrowth C. 
LanC-like protein 1  O43813 Mem Signaling C, CJD, R. 
Microtubule-associated protein 
1A  




ase A  
P62937 Golgi Protein refolding A, R. 
Peroxiredoxin-2  P32119 Cy Redox homeostasis R. 
Phosphoglycerate kinase 1  P00558 Cy Carbohydrate metabo-
lism 
All. 
Quinone oxidoreductase  Q08257 Cy mRNA processing CJD, R. 
Serine/threonine-protein phos-
phatase PGAM5 
Q96HS1 Mit Necrosis R. 
Synaptotagmin-1  P21579 Mem Neurotransmission C, R. 
Trifunctional enzyme subunit 
beta 
P55084 Mit, ER Lipid metabolism CJD. 
Tubulin beta-3 chain  Q13509 Cysk Axon maintenance C, R. 
Voltage-gated potassium chan-
nel subunit beta-2  







Figure 28: Disease-specific distribution of Aβ interactors isolated from FA-soluble fractions 
of controls, sAD and rpAD. The signature of Aβ-interacting partners was obtained by identifying 
the proteins purified through co-IP of pooled samples from each group (n = 3). The figure depicts 
the disease-specific distribution of these interacting partners. 
Additionally, in a separate experiment, the proteins that copurified with Aβ fibrils (seeds for Aβ 
RT-QuIC) and have the potential to function as accessory proteins for Aβ aggregation were also 
identified. The replicates from each experimental group were pooled to improve the quantity and 
detection of proteins through LC-ESI MS/MS. The dataset was then searched for targets that are 
amyloidogenic, promote amyloidogenesis and prevent fibrillization of amylogenic proteins and 
the results are presented in Figure 29. The literature supporting the pro- and anti-amyloidogenic 
capabilities of selected targets is detailed in the discussion. Although the distribution was not very 
specific, sAD cases showed decreased levels of proteins that prevent fibrillization of Aβ in com-
parison to rpAD. Moreover, the concentration of amyloidogenic proteins, that may potentiate fi-
brillization via cross-seeding, was also higher in sAD cases. These differences may underlie dis-
tinct aggregation kinetics of sAD and rpAD seeds in RT-QuIC reactions. The dataset was also 
analyzed for proteins that were reported in the former datasets as Aβ interactors and the results are 






Figure 29: Relative concentration of pro- and anti-fibrillization accessory proteins copurified 
with fibrils using differential ultracentrifugation. The graph depicts the differences in the spec-
tral counts of pooled samples from sAD, rpAD and controls. sAD cases had lower concentrations 
of anti-fibrilization proteins in comparison to rpAD cases. The spectral counts were normalized 
for each protein and the respective Z-scores were used for this plot. Since the dataset was obtained 
from pooled samples, individual differences were not analyzed statistically.  
3.4.1  Comparative analysis of Aβ-modulated pathways in sAD and rpAD 
The biological functions of potential Aβ interactors isolated from FA-soluble fraction from various 





cases, Aβ-interactors predominantly modulated neurotransmission, neurogenesis (cell cy-
cle/growth/development) and protein folding (chaperones), whereas a majority of Aβ interactors 
from sAD brains affected the replication, transcription, translation, transport of biomolecules and 
various metabolic pathways (Figure 30). Owing to the physiological function of Aβ, Aβ-interactors 
from control brains modulated pathways involved in immune response and maintaining the struc-
tural integrity of tissues. The interactors that were common in all groups were mainly chaperones 
and antimicrobial agents.   
 
Figure 30: Common functional categories of Aβ-interacting partners extracted from FA-sol-
uble fractions. The graph shows the relative percentage of proteins from all three experimental 
groups in each functional category. The functions of all proteins in the dataset were annotated 






An understanding of the discrete pathological mechanisms that lead to the presentation of various 
clinical subtypes of AD, especially the relatively newly discovered rpAD, are unknown to date. 
Previous studies have reported that rpAD cases are not significantly different from sAD cases with 
respect to markers for inflammation and tissue damage or the distribution of plaques and tangles 
(Schmidt et al., 2012; Abu-Rumeileh et al., 2018). However, proteomic and biophysical studies, 
especially those targeting the Aβ peptide, presented variations in Aβ as a promising target to un-
derstand the molecular differences among these clinical variants of AD (Cohen et al., 2015; Qiang 
et al., 2017). Expanding on these findings, the present study establishes the presence of previously 
underrepresented Aβ proteoforms in sAD and rpAD brains, gives an insight into the biosynthesis 
and relative quantities of these proteoforms and provides evidence for their distinct three-dimen-
sional morphologies, interactions and toxicities.  
4.1 The utility of common proteomic techniques for the analysis of Aβ  
The evolution of neurodegenerative proteinopathies into the study of specific proteoforms, rather 
than being limited to one target amyloidogenic protein, has challenged the utility of many previ-
ously common proteomic techniques. Furthermore, Aβ itself can readily aggregate, bind to lab-
ware and attach to columns used for fractionation, rendering many biochemical techniques useless. 
Several techniques were therefore tested for the separation and identification of Aβ proteoforms. 
To resolve minor differences in the sequences of Aβ proteoforms, 1D-PAGE was replaced by the 
recently revived 2D-PAGE coupled with IB analysis. The first method of choice for their identifi-
cation was LC-ESI MS/MS (in both bottom-up and top-down mode) owing to its capability to not 
only identify but also to sequence the isolated proteoforms (Wildburger et al., 2017). However, 
despite extreme measures to avoid loss of these highly hydrophobic peptides, several proteoforms 
did not elute from the column and the ones that were detected by analyzer were multiply charged 
and resulted in bottom-up inference problem or a complicated analysis. The overall results were 
highly non-reproducible. Hence, the techniques that depended on fractionation or electrospray ion-
ization proved to have limited utility for the current study. MALDI coupled with ToF analyzer was 
then selected for its capability to generate singly ionized proteoforms, uncomplicated annotation 




2018). The results obtained with MALDI-MS fulfilled the requirements of the experiment and 
were utilized for further analysis. 
4.2 Heterogeneity in the signature of Aβ proteoforms from sAD and rpAD 
samples  
2D-PAGE has been used by several groups previously for the characterization of proteoforms of 
APP and its downstream products (Newton et al., 2006; Bibl et al 2006; Sergeant et al 2003; Maler 
et al., 2007; Schieb et al., 2011). For an efficient detection of the endogenous signature of Aβ 
proteoforms from brain tissue, IP was coupled with 2D-PAGE-IB. Aβ was detected as pentamers, 
hexamers and dodecamers in control, sAD and rpAD cases but monomeric species were detected 
in FA-soluble fractions of the two latter groups only. As the presence of Aβ pentamers, hexamers 
and dodecamers is an experimental artifact in SDS-PAGE experiments, the annotation of spots 
was limited to monomeric species (Watt et al., 2013; Pujol-Pina et al., 2015). Similar to the data 
reported for sAD cases, major spots were detected at a pI of 5.31 (Aβ40 and Aβ42), 5.76 (shorter 
C-terminally truncated Aβ proteoforms) and 6.27 (Aβ4-42) in both experimental groups (Sergeant 
et al., 2003). Although the unavailability of proteoform-specific antibodies limited further analysis 
of these spots, it is noteworthy that while a greater variety was detected within the monomeric 
species in sAD cases, the rpAD brains featured more spots as higher-order aggregates, hinting at 
their differential capability to aggregate in response to SDS in the gels.  
In contrast to former 2D-PAGE studies, where peptides were identified using bottom-up prote-
omics, we utilized top-down MALDI-ToF to avoid alterations due to tryptic digestion. The low 
molecular weight of Aβ allowed its detection through this technique without any further fraction-
ation thereby avoiding additional purification and washing steps that usually result in the loss of 
peptides. Previously, MALDI-MS has been reported as a valuable tool for the identification of Aβ 
signature in the CSF (Gelfanova et al., 2007; Portelius et al., 2010).  
In the current dataset, a total of 33 distinct proteoforms were identified and Aβ40, Aβ42, Aβ4-42 as 
well as pAβ11-42 were the most abundant proteoforms in sAD and rpAD cases. Recent studies con-
ducted on sAD brains also reported these targets as the most abundant Aβ proteoforms in the in-
soluble (FA-soluble) fraction of sAD brains (Portelius et al., 2010; Wildburger et al., 2017). Un-
expectedly, apart from one rpAD sample (rpAD1, Figure 12), none of the samples presented sub-




the other hand, occurred more frequently in either sAD (Aβ1-12, Aβ2-14, Aβ3-14, Aβ15-38) or rpAD 
(Aβ5-27 and Aβ9-40) but their presence also varied among individual samples in each experimental 
group. Pyroglutamate proteoforms were frequently detected in the plaque associated proteome of 
both sAD and rpAD cases. Pyroglutamylation is known to increase the aggregation propensity of 
various proteoforms and the AD-associated behavioral deficits, hence its presence indicates more 
toxic counterparts of Aβ proteoforms (Wittnam et al., 2012; Sofola-Adesakin et al., 2016). The 
exact roles of a majority of these subtype-specific proteoforms are yet to be elucidated. 
A comparison of this data set with that reported for brain and CSF cohorts from sAD and its clinical 
variants by other groups is summarized in Table 8. Other than the aforementioned major pro-
teoforms, the signature appeared to be highly heterogeneous among various studies on brain sam-
ples. The CSF signature presented an even greater variation among the two mentioned studies. 
Although the intersubject variability among studied samples is now generally accepted to play a 
role in heterogeneity observed for Aβ proteoforms within and between various cohorts, alterations 
in signatures due to variations in purification and identification methodologies cannot be ignored 
(Condello et al., 2018).  
Table 8: Comparison of the Aβ proteoform signature reported for AD cases in the brain and 
CSF samples by various groups. Presence of a proteoform is indicated by ‘+’ sign while their 
absence is shown by ‘-’ sign. The proteoforms detected in all brain studies for sAD cases are 























et al., 2007 
(sAD CSF) 
Aβ1-12 + - - - - - 
Aβ1-13 - - - - + - 
Aβ1-14 - - - - + - 
Aβ1-15 - - - - + - 
Aβ1-16 - - - - + - 
Aβ1-17 - - - - + - 
Aβ1-18 - - - - + - 
Aβ1-19 - - - - + - 
Aβ2-13 + - - - - - 
Aβ3-14 + - - - - - 
Aβ2-14 + - - - - - 
Aβ11-33 + - - - - - 
Aβ11-34 - - + - -  
Aβ2-20 + - - - - - 




Aβ1-20 + - + - + - 
Aβ14-38 + - - - - - 
Aβ5-27 + - - - - - 
Aβ5-29 + - - - - - 
Aβ1-26 + - - - - - 
pAβ11-40 + - - - - - 
Aβ1-27 + - - - - - 
pAβ11-42 + + + + - - 
Aβ11-42 + + + + - - 
Aβ9-40 + - - + - - 
Aβ11-43 + - - - - - 
Aβ8-40 + - + - - - 
Aβ10-42 - - - + - - 
Aβ9-42 + - - + - - 
Aβ8-42 + + + + - - 
Aβ7-42 - - - + - - 
Aβ1-30 - - - - + - 
Aβ1-33 - - + - + + 
Aβ1-34 + - + - + + 
Aβ4-40 + + + + - - 
Aβ5-40 - - - + - - 
Aβ5-42 + + + + - - 
Aβ1-37 + - - + + + 
Aβ2-38 - - - + - - 
Aβ1-38 + - - + + + 
Aβ1-39 - - - + + + 
Aβ3-40 + - - + - - 
pAβ3-40 - - - + - - 
Aβ4-42 + + + + - - 
Aβ3-42 - - + + - - 
pAβ3-42 + + + + - - 
Aβ1-40 + + + + + + 
Aβ2-42 + + - + - - 
Aβ1-41 + - - - - - 
Aβ1-42 + + + + + + 
Aβ1-43 - - - + - - 
 
Since the MALDI MS experiments lacked labelled Aβ proteoforms as internal standards, ELISA 
was used instead of this dataset for quantification. As expected, the amounts of all proteoforms 
were higher in sAD and rpAD in comparison to controls, however, a significant difference was 
only evident in the case of C-terminally truncated proteoforms in FA-soluble fraction. No differ-
ences could be observed between sAD and rpAD in case of IB for AβTotal and either ELISA test. 
Interestingly, the Tris-soluble fraction featured higher N-terminally truncated Aβ proteoforms in 




cated Aβ proteoforms was also evident in our MALDI MS experiments and a trend has been ver-
ified previously in other studies (Sergeant et al., 2003; Miravalle et al., 2005). This trend was 
significant in our sAD samples but the differences in the other two targeted groups were not sig-
nificant.  
The sequence of proteoforms dictates their folding, aggregation and toxicities. It is now known 
that the proteoforms with longer C-terminal are more amyloidogenic and feature highly ordered 
structures with a greater percentage of beta-sheets. Proteoforms lacking an intact C-terminal do-
main are less prone to aggregation and form disordered aggregates (Vandersteen et al., 2012). The 
known relevance of extended N-terminal, on the other hand, is limited to pyroglutamylation within 
this domain and this modification is shown to increase the aggregation propensities by up to 250-
fold (Schilling et al., 2006). Aβ5-42, Aβ11-40 and Aβ11-42 are more prone to aggregation than their 
full-length counterparts and have been reported to cofibrillize with Aβ40 and Aβ42 (Barritt and 
Viles, 2015; Barritt et al., 2017; Weiffert et al., 2019).  
Most of the studies targeting cellular toxicities have been limited to Aβ40 and Aβ42 only. However, 
Aβ3-42, pAβ3-42, Aβ4-40 and Aβ4-42, have also been postulated to potentiate ion channel formation, 
to trigger the loss of neurons and to mediate behavioral deficits (Bouter et al., 2013; Gunn et al., 
2016; Dunys et al., 2018). Others, as reported for several C terminally truncated Aβ proteoforms, 
can be intermediates of various Aβ degradation and clearance pathways (Olsson et al., 2014). 
Presence of some C-terminally truncated shorter peptides, including Aβ1–37, Aβ1–38 and Aβ1–39, has 
been shown to prevent the toxic effects of Aβ1-42 although the exact mechanism behind this change 
is unknown (Moore et al., 2018). Moreover, although the aggregation propensities of Aβ11-40 and 
Aβ11-42 and their pyroglutamate variants have been reported to be very high, their toxicity in cell 
culture experiments is lower than other known proteoforms (Sohma et al., 2013). 
4.3 The implications of higher BACE1 levels in rpAD  
Theoretically, the reduced expression of enzymes involved in the clearance of Aβ and/or upregu-
lation of enzymes that modulate the amyloidogenic pathway should exacerbate AD. However, 
despite several studies, the expressional profiles of most Aβ-processing enzymes are not fully es-
tablished. ADAM-10, the major α-secretase, is believed to be reduced in AD (Colciaghi et al., 




many discrepancies in the literature with reference to its generation, expression and activity there-
fore, no consensus has been reached (Stockley et al., 2007). No significant differences have been 
found among sAD, fAD and control cases in the expression of PSEN1, a key component of γ-
secretase (Hendriks et al., 1997). The expression and activity of IDE also showed no differences 
among AD and control cases (Wang et al., 2010). The expression of plasmin is downregulated in 
AD (Ledesma et al., 2000). Individually, none of these enzymes showed significant differences in 
expression in our cohort.  However, it is worth mentioning that in all of the previous studies, and 
the current study, all samples were tested post-mortem, although Aβ pathology begins very early 
in the disease course. Thus, the relative levels of enzymes reported might not depict an accurate 
picture of the changes that lead to differential progression in clinical subtypes of AD.  
Nevertheless, a significantly higher ratio of BACE-1, in comparison to ADAM-10, was seen in 
rpAD in comparison to sAD. Although the activity of these enzymes still needs to be confirmed, 
this trend indicates higher cleavage of Aβ via the amyloidogenic pathway, consequently leading 
to the greater formation of amyloidogenic proteoforms. The relatively higher ratio of this β-secre-
tase accompanied with no alterations in Aβ clearance enzymes would lead to a greater plaque 
burden and possibly exacerbate the disease symptoms. 
4.4 Differences in amplification capabilities of sAD and rpAD seeds  
With recent advances in in vitro seeding assays, especially the RT-QuIC assay, it is now possible 
to define clinical subtypes of most neurodegenerative proteinopathies with reference to the aggre-
gation kinetics of various strains of the amyloidogenic proteins (Wilham et al., 2010). These alter-
ations in aggregation kinetics can translate to distinct biochemical properties, stabilities, transmis-
sion and disease phenotypes (Rasmussen et al., 2017). Although the idea was initially limited to 
PrPC, the field has taken many prion-like proteins, including Aβ, under consideration (Di Fede et 
al., 2018; Candelise et al., 2019; Saijo et al., 2019). Structure-sensitive probes have identified dis-
tinct subtypes of AD previously based on alteration in the 3D conformations of resident Aβ (Ras-
mussen et al., 2017; Condello et al., 2018). Given the lack of expressional differences in major Aβ 
proteoforms in the MALDI MS dataset, this study also targeted the differences among Aβ strains 
extracted from sAD and rpAD brains.  
Unlike the RT-QuIC assays for PrPC and α-synuclein, the lack of understanding and availability 




kinetics. Most of these peptides are prone to self-aggregation and mask differences generated by 
the brain-derived seeds. However, fibrillization only occurs when a critical threshold of peptide 
concentration is reached, after which the generation of characteristic fibrils becomes independent 
of initial concentration and becomes dependent on the biochemical nature of the seeds (Novo et 
al., 2018; Di Fede et al., 2018). The efforts to optimize the seeding assay employed in the current 
study were therefore preliminary targeted to adjust the quantity of substrate in a way that self-
aggregation is limited to a minimum.  
Based on the major proteoforms detected by MALDI MS in the current study, a combination of 
Aβ40 and Aβ42 was used as seeds for RT-QuIC reactions in contrast to using a higher concentration 
of either proteoform in independent assay which leads to self-aggregation. Prior evidence suggests 
that cross-seeding does not occur among these proteoforms, therefore their use as seeds in a single 
reaction was not problematic (Xiao et al., 2015). The results confirm that, in the absence of seeds, 
the substrate does not aggregate and generate a comparable signal or higher-order aggregates. 
Moreover, despite the fact that Aβ pathology is common in healthy controls as well, the signal 
suggests the presence of seeds that do not aggregate in the reaction conditions used.  
Although the protocol employed here is still in the primary stages of development, subtle differ-
ences were observed among targeted clinical variants. sAD cases were observed to aggregate faster 
with a shorter lag phase and steeper curves in comparison to rpAD cases (Figure 31). These 
changes in aggregation kinetics reflect directly on the seeding capabilities of seeds extracted from 
sAD and rpAD. In a similar study with Aβ RT-QuIC, sAD and fAD samples with PSEN mutations 
showed the faster aggregation and steeper slopes in comparison to fAD cases with APP mutations 
(Di Fede et al., 2018). It is conceivable that a longer lag phase reflects the presence of Aβ as the 
more toxic oligomeric species for a longer duration in the brain. As the generation of mature fibrils 
and plaques is a protective physiological measure to prevent Aβ toxicity, their delayed generation 
suggests possible pathological implications. Collectively, these changes can lead to more neuro-





Figure 31: The aggregation kinetics of misfolded Aβ in sAD and rpAD. (A) The seeding of 
amyloidogenic proteins involves the conversion of monomeric seeds into aggression-prone oligo-
meric nuclei (lag phase), followed by exponential conversion of oligomers into protofibrils and 
mature fibrils (exponential phase)  until the reaction reaches a plateau due to a lack of monomers 
or other rate-limiting factors (stationary phase). (B) Kinetic curves for sAD- and rpAD-derived 
RT-QuIC reactions depict inherent differences in the seeding capabilities of seeds extracted from 
distinct variants of AD.  
4.4.1 The role of accessory proteins in Aβ seeding  
Other than the intrinsic differences in the biochemical nature of seeds, amyloidogenesis is also 
affected by many environmental factors including pH, salt concentration and the presence of spe-
cific cofactors (Sikkink and Ramirez-Alvarado, 2008; Pfefferkorn et al., 2010). As the pH and salt 
concentrations are constant under in vitro conditions, the proteins and other biomolecules co-pu-
rified with the seeds are a major source of influence on the seeding capabilities of brain-derived 
fibrils. The impact of these molecular cofactors, including proteoglycans, lipids and polyanions, is 




Nguyen et al., 2015; Fichou et al., 2018). The current project also targeted these cofactors, specif-
ically those proteinaceous in nature, to further elucidate the reasons underlying the differences in 
the RT-QuIC profiles between sAD and rpAD brains.  
A majority of proteins identified in this dataset were cytoplasmic proteins that have been previ-
ously reported to undergo changes in solubility in response to Aβ pathology, leading to their iso-
lation from the insoluble fraction, rather than the soluble fraction of brain proteome (Xu et al., 
2013). The analysis was therefore focused on the targets that have been previously associated with 
assisting or inhibiting the fibril formation of prions or prion-like proteins. Intrinsically disordered 
proteins, which have the potential to form amyloidogenic or amorphous aggregates, were also 
added to the list since several of these candidates can cross-seed Aβ and implicate amyloid for-
mation (Furukawa et al., 2009; Keefer et al., 2017; Nizynski et al., 2018; Lim, 2019). The key 
targets copurified with seeds under the optimized experimental conditions and their potential role 
in promoting or demoting protein aggregation are listed in Table 9. 
The heterogeneity among the clusters of proteins that impact amyloidogenesis directly gives an 
insight into the environment of fibrils in the brain. The proteins involved in promoting fibril for-
mation were highly enriched in rpAD cases whereas sAD cases presented a higher amount of pro-
teins that can cross-seed Aβ. The anti-amyloidogenic proteins appeared to be equally distributed 
among the two clinical variants of AD (Figure 29). Collectively, these changes can affect the am-
yloid formation and contribute towards discrepancies observed in kinetic curves.  This list of pu-
tative accessory proteins is being validated by seeding Aβ under different concentrations of the 




Table 9: List of potential accessory proteins purified with Aβ fibrils. The proteins, in addition to Aβ, extracted as fibrillar fraction 
via differential centrifugation were identified and their potential to interfere with amyloid formation was established through an exten-
sive literature review. The targets that may influence amyloidogenesis either by aiding fibril formation, inhibiting their assembly or 
cross-seeding Aβ are listed below. Additionally, the proteins in this dataset, that were found to interact with Aβ in the IP experiments 
conducted in the current study, have been stated as interactors.  
Proteins Accession # Aβ Interactor Role Specificity Reference 
1,4-alpha-glucan-branching 
enzyme  
Q04446 No Prone to misfolding and aggrega-
tion 
C, rpAD Froese et al., 2015 
14-3-3 protein  P63104 Yes Promotes formation of aggresome 
to avoid amyloid-associated tox-
icity  
All Shimada et al., 2013 
26S proteasome non-ATPase 
regulatory subunits 
Q99460 Yes Aberrant activity aids the accumu-
lation of misfolded proteins 
All Ciechanover and 
Kwon, 2015 
26S proteasome regulatory 
subunits 
P62333 No Aberrant activity aids the accumu-
lation of misfolded proteins 
All Ciechanover and 
Kwon, 2015 
40S ribosomal proteins P46783 Yes Stimulates aggregation All Pathak et al., 2017 
60S acidic ribosomal pro-
teins 
P05388 Yes Stimulates aggregation All Pathak et al., 2017 
Adipocyte plasma mem-
brane-associated protein  
Q9HDC9 No Suppresses Aβ aggregation All Mosser et al., 2014 
AFG3-like protein 2  Q9Y4W6 No Intrinsically disordered protein as-
sociated with spinocerebellar 
Ataxia 
All Das and Mukhopadh-
yay, 2011 
Agrin  O00468 No Accelerates amyloidogenesis All Cotman et al., 2000 
Alpha-1-antichymotrypsin  P01011 No Inhibits fibril formation  C, rpAD Eriksson et al., 1995 
Alpha-crystallin B chain  P02511 Yes Inhibits fibril formation All Raman et al., 2005 
Amine oxidase  P21397 Yes Increases the rate of aggregation 
and size of aggregates indirectly 
All Chen et al., 2006 
Annexins P04083 Yes Degradation of Aβ and clearance 
of fibrils 
All Ries et al., 2016 
Apolipoprotein E  P02649 Yes Enhances Aβ deposition into 
plaques  
sAD, rpAD Endo et al., 2019 
Beta-2-microglobulin  P61769 No Amyloidogenic All Drüeke., 2000 
Carbonic anhydrase 4  P22748 No Amyloidogenic All Rana et al., 2008 









Cathepsin D  P07339 Yes Degrades Aβ All Sakamoto et al., 2006 
CDGSH iron-sulfur domain-
containing protein  
Q04446 No Intrinsically disordered protein as-
sociated with Wolfram syndrome 
All Das and Mukhopadh-
yay, 2011 
Charged multivesicular 
body protein 4b  
Q9H444 Yes Clearance of aggregating proteins sAD Rusten et al., 2008 
Cytochrome c  P99999 No Prone to amyloid formation All Lin et al., 2016 




P09622 Yes Intrinsically disordered associated 
with Leigh syndrome 
All Das and Mukhopadh-
yay., 2011 
Dynein heavy chain  Q9P2D7 No Involved in trafficking and clear-
ance of aggregates 
sAD, rpAD Rubinsztein et al., 2006 
E3 ubiquitin-protein ligase  Q7Z6Z7 No May contribute to clearance All Khandelwal and 
Moussa, 2010 
Ferritin  P02794 No Disrupts aggregates by scavenging 
iron.  
All Balejčíková et al., 2019 
Fibrinogen  P02671 Yes Cross-seeding All Ahn et al., 2010 
Galectin P09382 Yes Promotes oligomerization C, sAD Tao et al., 2020 
Glyceraldehyde-3-phosphate 
dehydrogenase  
P04406 Yes Increases aggregation by blocking 
chaperones 
All Muronetz et al., 2017 
Heat shock proteins P10809 Yes Inhibits early stages of aggrega-
tion  
All Webster et al., 2019 






No Promotes fibril formation All Liu et al., 2016 
Histones P07305 Yes  Favors the aggregation of Aβ and 
stabilize aggregates 
All Duce et al., 2006; Liu 
et al., 2016 
Huntingtin  P42858 No Amyloidogenic sAD Huang et al., 1998 
Hyaluronan and proteogly-
can link protein  
P10915 Yes Enhances aggregation All Wang et al., 2019 
Immunoglobulin gamma-1  P0DOX5 Yes Anti-amyloidogenic All Valls-Comamala et al., 
2017 
Kinesin family member 1A  X5D7J0 No Inhibits aggregation All Zheng et al., 2016 
Kinesin heavy chain isoform  O60282 No Inhibits aggregation All Zheng et al., 2016 
Lamin P20700 Yes Cross-seeding All Groh et al., 2017 
Laminin subunits P24043 No Inhibits Aβ fibrillation All Bronfman et al., 1998 
Low-density lipoprotein re-
ceptor-related protein 1B  




Major prion protein  B2R5Q9 Yes Stabilizes oligomers; cross-seed-
ing 









Yes Amyloidogenic All Nizynski et al., 2017  
Myelin-oligodendrocyte gly-
coprotein  
Q16653 No Amyloidogenic All Araman et al., 2018 
Myosin P35580 Yes Amyloidogenic All Komatsu et al., 2006 
Neurofilament  P12036 No Prone to aggregation All Lin and Schlaepfer., 
2006 
Neuronal-specific septin-3  Q9UH03 Yes Amyloidogenic All Ortore et al., 2015 
Neutrophil defensin 1  P59665 Yes Induces amyloid formation C, sAD Horn et al., 2012 
Nucleobindin-1  Q02818 No Inhibits fibril formation C, rpAD Bonito-Oliva et al., 
2017 
Profilin-2  P35080 Yes Binds to oligomers and prevents 
fibril formation 
All Posey et al., 2018 
ProSAAS  Q9UHG2 Yes Blocks aggregation and toxicity All Jarvela et al., 2016 
Pyruvate kinase  A0A024R5
Z9 
No Amyloidogenic All Grignaschi et al., 2018 
RuvB-like 1 /2 Q9Y265 Yes Disaggregate amyloid fibrils All Zaarur et al., 2015 
Serum albumin  P02768 No Prevents Aβ aggregation C, sAD Finn et al., 2012 
Spectrin  Q01082 No Amyloidogenic sAD, rpAD Morel et al., 2006 
Superoxide dismutase [Cu-
Zn]  
P00441 Yes Amyloidogenic C, AD Khan et al., 2017 
Superoxide dismutase [Mn]  P04179 No Amyloidogenic  All Khan et al., 2017 
Surfeit locus protein 4  O15260 No Intrinsically disordered protein as-
sociated with Leigh syndrome 
All Das and Mukhopadh-
yay, 2011 
Synaptojanin-1  O43426 No Involved in Aβ Clearance sAD, rpAD Zhu et al., 2013 
TAR DNA-binding protein 
43 TDP43 
Q13148 No Amyloidogenic, cross-seed Aβ All Fang et al., 2014 
Transitional endoplasmic re-
ticulum ATPase VCP 
P55072 Yes Intrinsically disordered protein as-
sociated with FTD 
C, sAD Das and Mukhopadh-
yay, 2011 
Tripeptidyl-peptidase 1  O14773 Yes Destabilizes fibrillar Aβ All Solé-Domènech et al., 
2018 





4.5 Structure-function relationship of brain-derived fibrils 
The technical difficulties in extracting and amplifying brain-derived Aβ fibrils have limited most 
of the studies to synthetic proteoforms. Among the few nuclear magnetic resonance (NMR) studies 
and imaging experiments conducted on brain-derived fibrils, polymorphisms among generated 
structures have been the most prominent observation (Lu et al., 2013; Qiang et al., 2017; Condello 
et al., 2018). Interestingly, the existence of a greater heterogeneity, especially for Aβ40 fibrils, has 
been associated with the rapid progression observed in some AD cases (Qiang et al., 2017). In the 
current study, the structure of fibrils generated via RT-QuIC assays was visualized using confocal 
and atomic force microscopy. Surprisingly, although the aggregation of rpAD fibrils appeared to 
be slower than sAD fibrils, they featured the presence of larger and more polymorphous (both 
fibrillar and amorphous) aggregates in comparison to sAD cases. In contrast, sAD-derived reac-
tions had regular well-defined fibrils.  
Previous studies have also attributed these differences to alterations in inherent charges of the 
substrate, hydrophobicity and the capability of proteins to generate secondary structures required 
for nucleation (Zapadka et al., 2017). Since similar substrate was used for all reactions, the altera-
tions in inherent charges may not have played a major role. To access the alterations in secondary 
structure, FTIR spectroscopy was performed on the brain-derived fibrils. However, no shifts in 
peaks were observable for either clinical subtype in these experiments indicating similar propor-
tions of β-sheets, α-helices and other secondary structures. It can, therefore, be postulated that the 
larger structures observed for rpAD may be products of highly hydrophobic fibrils that have higher 
propensity to bind with each other and generate a plaque-like morphology. As secondary nuclea-
tion is dependent on the availability of fibril surface and rpAD-derived fibrils are buried within 
larger structures, these results also explain why rpAD cases reached the stationary phase at a lower 
absorbance in comparison to sAD cases.  
The structure of aggregates is closely associated with their mechanisms of toxicity (De et al., 
2019). Neuronal cells were treated with brain-derived fibrils and the relative toxicities of sAD and 
rpAD fibrils were accessed but no significant differences were evident among the two clinical 
variants. However, it is noteworthy that the experiment was conducted using the end products of 




fibrillar aggregates. In vivo mechanisms of Aβ toxicity were also assessed to address the alterations 
within the sAD and rpAD brains which will be discussed in the following section. 
4.5.1 Aβ-induced aberrations in cellular pathways  
Protein-protein interactions play a keen role in physiological and pathological functioning of neu-
rons. The interactions of Aβ with various biomolecules can provide useful insights into the patho-
biology of clinical variants of AD. Experiments conducted using co-IP identified proteins involved 
in growth, neurotransmission, metabolism and transport that aid Aβ by propagating its toxicity to 
various organelles within the neurons and other brain cells. Both Tris-soluble and FA-soluble pools 
of Aβ were targeted and contrast was observed in the functional pathways modulated in sAD and 
rpAD brains. However, the targets identified in FA-soluble fraction can only be interpreted as 
putative interactors, rather than presenting physiological interactions, due to the effect of FA treat-
ment on protein chemistry.  
A majority of Aβ interactors from sAD brains affected the cellular machinery involved in replica-
tion, transcription, translation and various metabolic pathways. Previous studies have reported the 
inhibition of protein synthesis as the major pathway affected by aberrant interactions of Aβ in 
relation to sAD (Virok et al., 2011). Ribosomal proteins, specifically ribosomal proteins L23A, 
L31, S13 and S17 have been found to be upregulated in sAD in comparison to rpAD (Garcia-
Esparcia et al., 2017). In rpAD cases, Aβ interactors primarily modulated neurotransmission, neu-
rogenesis and protein folding, and the dataset confirmed that Aβ species in these cases may impart 
toxicity through the modulation of pathways different from sAD cases. Drummond et al., (2017) 
also reported the enrichment of proteins involved in synaptic dysfunction in plaques from rpAD 
cases. Owing to the physiological function of Aβ, Aβ interactors from control brains modulated 
pathways involved in immune response and maintaining the structural integrity of tissues. The key 
interactors and their implications on the pathobiology of AD have been detailed below.  
4.5.1.1 Immune response  
One of the few physiological roles of the Aβ peptide reported to date is its capability to act as an 
antimicrobial agent against viruses and bacteria (Brothers et al., 2018). The generation of Aβ oli-
gomers and fibrils increases in the incident of an infection and is reported as one of the earliest 
responses of the innate immune system. Aβ fibrils interact with membranes of pathogens to create 




elongating fibrils (Gosztyla et al., 2018; Moir et al., 2018).  The current study shows that, in com-
parison to rpAD (1%), a greater percentage of Aβ interactors in controls (15.3%) and sAD (6.25%) 
cases were involved in the modulation of the immune response in the FA-soluble fraction of brain 
proteins. These interactors (arginase, BPI fold-containing family A, eukaryotic initiation factor 
4A-I, and ubiquitin carboxyl-terminal hydrolase) are shown to be involved in innate immunity and 
play a role in facilitating host-virus interactions. These targets can provide an insight into the path-
ways regulated by Aβ to facilitate its role as an antimicrobial agent under physiological conditions. 
No immunity-related interactors were detected in Tris-soluble fraction, possibly due to a greater 
involvement of Aβ fibrils, but not monomers and oligomers, in the immune response.  
4.5.1.2 Signal transduction  
AD pathology is a product of aberrations in several key pathways, including Wnt/β-catenin, Notch, 
mitogen-activated protein kinase (MAPK), rapamycin (mTOR) and calcium signaling pathway 
(Mizuno et al., 2012). Together, these alterations are responsible for the reorganization of the cy-
toskeleton, neuronal dysfunction, cell cycle abnormalities, Aβ production, mismetabolism and 
dysregulated recycling of biomolecules (Woo et al., 2009; Hermes et al., 2010; Oddo, 2012; Palo-
mer et al., 2019). Previous studies have reported a direct interaction of Aβ with RAGE, PrPC and 
insulin receptors and aberrant modulation of their downstream pathways (Zhao et al., 2008; Smith 
et al., 2017). A direct relationship between Aβ administration and mTOR signaling has also been 
reported (Oddo, 2012). This evidence highlights the direct involvement of Aβ in disrupting sur-
vival pathways. However, no previous studies have targeted the individual culprits responsible for 
inducing Aβ-directed alterations in these pathways. 
Interestingly, serine/threonine-protein phosphatase PGAM5, a key regulator of programmed cell 
death caused by tumor necrosis factor (TNF-α), oxidative stress and calcium-induced excitotoxi-
city, was seen to interact with Aβ in Tris-soluble fraction of rpAD brains (Wang et al., 2012). The 
GTPase KRas, a component of the MAPK pathway, showed a similar specificity. Moreover, 
peroxiredoxin, involved in the activation of the MAPK pathway, was also observed to interact 
with Aβ in rpAD, but not sAD, brains. Previous studies have also verified a direct impact of oli-
gomeric Aβ on the MAPK pathway (Young et al., 2009). LanC-like protein 1, involved in the 
epidermal growth factor receptor pathway, was reported to interact with Aβ in all experimental 




A similar pattern was observed in Aβ interactors isolated from FA-soluble fraction as well, with a 
greater percentage of identified proteins involved in signal transduction in rpAD cases as compared 
to sAD. Several of these targets, including APC membrane recruitment protein 2, dimethylarginine 
dimethylaminohydrolase, Na/H exchange regulatory cofactor NHE-RF1, Protein NDRG1 and leu-
cine-rich repeat flightless-interacting protein 2 are involved in Wnt/β-catenin pathway and hint at 
serious aberrations within pathway in rpAD brains (Liu et al., 2005; Tanneberger et al., 2011; 
Ardura and Friedman, 2011; Liu et al., 2012; Ye et al., 2017).   
4.5.1.3 Structural roles  
Cytoskeletal proteins play a key role in the maintenance of neuronal cell bodies. They are also 
responsible for axon guidance, the formation of dendritic spines and synaptic terminals. Therefore, 
dysregulation of the cytoskeleton can have a direct impact on neurotransmission and neuronal 
survival. The role of various cytoskeletal proteins in the pathophysiology of AD has been vigor-
ously targeted over the past few decades and several promising targets, including amyloidogenic 
tau protein, have emerged (Bamburg and Bloom, 2009). Furthermore, Aβ itself is directly involved 
in dysregulating the polymerization and post-translational modifications of various cytoskeletal 
proteins, directly impacting the trafficking of vesicles and organelles along the synaptic cytoskel-
eton (Henriques et al., 2010).  
Cytoskeletal interactors of Aβ associated with the Tris-soluble fraction of brain proteins included 
actin-related protein 2, Band 4.1-like protein 3, dihydropyrimidinase-related protein 2 and micro-
tubule-associated protein 1A. All of these proteins are involved in the organization of cytoskeleton, 
however, most of them, except for microtubule-associated protein 1A, were detected in rpAD and 
control brains only. Similarly, the FA-soluble fraction also identified a greater percentage of rpAD-
associated Aβ interactors (14.8%), in contrast to sAD (6.25%), to be involved in cytoskeletal or-
ganization and other structural functions. This observation further highlights the involvement of 
different pathways in the two distinct clinical variants of AD.  
4.5.1.4 Neurotransmission 
Cognitive dysfunction and memory loss are key clinical symptoms of AD and several other forms 
of dementia. Aβ contributes towards this pathological phenomenon by hindering the release of 




Russell et al., 2012). Aberrantly modified tangles contribute to synaptic toxicity by inhibiting ax-
onal transport, deregulating synaptic receptors and impairing dendritic spines (Tracy and Gan, 
2018). Together, these alterations affect synaptic plasticity resulting in worsening of memory def-
icits observed in patients.  
In the current dataset, Aβ was observed to interact with voltage-gated potassium channels in all 
experimental groups. However, its higher expression in sAD and rpAD can result in a higher dose-
dependent impairment of potassium channels and trigger a greater disturbance in neurotransmis-
sion. Aberrant expression of voltage-gated potassium channels and subsequent dysregulation of 
action potential have previously been associated with neurodegeneration (Angulo et al., 2004; 
Shirwany et al., 2007). Additionally, synaptotagmin-1 was detected in rpAD cases but not in sAD 
cases. Synaptotagmin-1 is involved in the release of neurotransmitters through its interactions with 
the SNARE complex and phospholipid membranes and has been previously reported to be in-
creased in AD-associated pathologies (Südhof et al., 2012; Öhrfelt et al., 2016). Furthermore, it 
has also been reported to implicate the generation of Aβ through its interaction with PSEN 1 
(Zoltowska et al., 2017). The functional categorization of interactors in FA-soluble fraction also 
revealed a greater number within rpAD (5.5%), in comparison to sAD (1.5%) and control brains 
(0%), to be involved in neurotransmission.  
4.5.1.5 Metabolism and cell cycle 
Insulin resistance, misprocessing of glucose, dysregulation of lipids, aberrant levels of cholesterol 
and reduced energy metabolism have been frequently associated with AD pathology, leading to its 
interpretation as a metabolic disorder. Together these alterations are believed to accelerate the 
accumulation of misfolded proteins (Grimm et al., 2007; Demetrius and Driver, 2013; Di Dome-
nico et al., 2017). Several proteins involved in energy and glucose metabolism were also fished 
out as interactors in Tris-soluble fraction. Adenylate kinase, ATP synthase and ADP/ATP trans-
locase, crucial elements for the generation and availability of ATP, were found to interact with Aβ 
in rpAD but not in sAD. Glycolytic enzymes, including citrate synthase, fructose-bisphosphate 
aldolase C and phosphoglycerate kinase, were commonly detected in both subtypes of AD. In the 
FA-soluble fraction, sAD cases showed a greater percentage (30%) of interactors to be involved 





Several proteins involved in cell cycle and neurogenesis were also found among the interactors. 
Neurons, unlike most of the other cell types, do not undergo mitosis in adults. Atypical initiation 
of cell cycle normally results in apoptosis, leading to a loss of neuronal tissue. Evidence in favor 
of Aβ-induced aberrant re-entry of neurons into the cell cycle and an associated increase in apop-
tosis has been presented in the past (Moh et al., 2011). An Aβ-induced decrease in adult neurogen-
esis and neuronal maturation is also being argued as some of the earliest changes in AD (Mu and 
Gage, 2011; Scopa et al., 2019).  In the FA-soluble fraction, 14% of the interactors in rpAD were 
found to be involved in cell cycle-related mechanisms in comparison to 6.2% and 7.3% in sAD 
and control cases, respectively. No interactors from this functional category were found in Tris-
soluble fraction.  
4.5.1.6 Transcriptional and translational machinery 
Alterations in ribosomes and protein synthesis have been frequently reported in AD over the last 
two decades (Ding et al., 2005). Interestingly, differential downregulation of ribosomal proteins 
has also been associated with rpAD (Garcia-Esparcia et al., 2017). In line with these findings, the 
current dataset also confirmed the involvement of many interactors, directly or indirectly, in the 
maturation of mRNA and translation of proteins, in the FA-soluble fraction of sAD (20%), rpAD 
(10%)  and controls (7%). However, in Tris-soluble fractions, the 40S and 60S ribosomal proteins 
were seen in all subentities except sAD.  
4.5.1.7 Redox pathways 
Oxidases and reductases constitute important components of the pathways involved in sustaining 
functions of cells (Dykens, 2007). Several of these enzymes, including flavin reductase, NAD(P) 
transhydrogenase and dihydropteridine reductase, were seen to interact with Aβ in both Tris- and 
FA-soluble fractions and highlight a probable effect of Aβ on the metabolism of ATP and other 
critical biomolecules. Aβ was also seen to interact with peroxiredoxin, a known antioxidant, in the 
FA-soluble fraction of all experimental groups. Peroxiredoxins have been previously implicated 




4.5.1.8 Chaperone activity 
A majority of chaperones, including heat shock protein 70, endoplasmic reticulum chaperone BiP 
and α-crystallin, were detected in all experimental groups in the FA-soluble fraction and consti-
tuted the largest functional category of overlapping proteins in various groups. Heat shock proteins 
and other chaperones are known to play a role in protein folding and clearance of misfolded pro-
teins and undergo expressional anomalies in AD pathology (Yoo et al., 2001; Wilhelmus et al., 
2007). Surprisingly, in FA-soluble samples, a greater number of interactors in rpAD cases than in 
sAD cases were chaperones highlighting probable differences in the folding and clearance of mis-
folded Aβ in the two variants. In the Tris-soluble fraction, peptidyl-prolyl cis-trans isomerase A, 
another chaperone, was present in sAD and rpAD cases only.  
4.6 Limitations and considerations  
Despite cautiously controlled conditions and optimized protocols, a few limitations have to be 
considered. Although MALDI-MS protocol employed in the current study has been a valuable tool 
for the analysis of Aβ in the past, our primary method of choice was a sequencing-based mass 
spectrometric technique. Sequencing provides a better insight into minor proteoform-specific 
changes, including posttranslational modifications, that are overlooked while manually annotating 
peaks. However, the hydrophobic nature of the target peptide rendered our LC-coupled MS/MS 
peptide sequencers useless and the annotation had to be conducted manually based on m/z ratios.  
Moreover, the genotyping of rpAD samples has been limited to APOε to date. The data for muta-
tions in Aβ-cleaving enzymes and other proteins that might influence APP processing and amy-
loidogenesis is the key to explaining differences in the signature and aggregation propensities of 
sAD and rpAD cases. Although the current project used the proteomic platform extensively, the 
speculations are only partially useful without understanding the genomic background.  
Lastly, the non-demented control samples employed in the current study were chosen age-matched 
with the diseased cases. However, non-demented individuals also exhibit Aβ pathology. The pres-
ence of Aβ, even at lower levels, in the absence of clinical symptoms can complicate several find-
ings especially the study of Aβ-cleaving enzymes and Aβ interactors. An analysis of cases without 
Aβ pathology can further justify the relative quantities of enzymes and provide a better insight into 
disease-specific interactors.  
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5. Summary and conclusion 
The molecular mechanisms involved in atypical rapid progression of Alzheimer’s disease (AD), 
as seen in rpAD, are not known. Subtle changes in Aβ-ome have been frequently associated with 
distinct phenotypic presentations of AD cases. The current project was aimed to define these clin-
ical variants based on alterations in the sequence, processing, folding and toxicity of distinct Aβ 
peptides and their associated proteoforms. An array of proteomic techniques was used in combi-
nation with various biophysical methods to characterize brain-derived Aβ from sAD and rpAD 
brains. Additionally, a comprehensive analysis of toxic mechanisms mediated by Aβ in sAD and 
rpAD was also conducted.  
Hybrid-IP, followed by 2D gel electrophoresis and top-down MALDI MS, was employed to isolate 
Aβ from FA-soluble fractions of sAD, rpAD and non-demented control brains to establish a sig-
nature of brain-derived proteoforms and 33 Aβ proteoforms were identified. Aβ40, Aβ42, Aβ4-42, 
Aβ11-42 and pyroglutamate Aβ11-42 were common in all sAD and rpAD cases, however, several 
shorter N-terminally and C-terminally truncated proteoforms showed disease-specific involve-
ment. Since the majority of prior studies have focused exclusively on Aβ40 and Aβ42, the exact 
function of these shorter peptides, presenting a disease-specific signature, remains unknown to 
date. Non-demented controls did not produce analyzable peaks due to the lower quantity of Aβ. It 
is noteworthy that sAD showed a greater variety among monomeric species of proteoforms, 
whereas the rpAD cases featured more proteoforms as multimers, hinting at their different capa-
bilities to aggregate in response to SDS in 2D GE.  
The semi-quantitative analysis of enzymes involved in the generation of Aβ yielded no differences, 
however, the ratio of BACE-1/ADAM-10 was significantly higher in rpAD samples than in sAD 
samples, indicating higher cleavage of Aβ via the amyloidogenic pathway. The overall amounts 
of APP, AβTotal and its differentially cleaved proteoforms were not significantly different among 
the sAD and rpAD cases, although both subtypes had amounts that were significantly higher than 
non-demented controls. In the case of Tris-soluble fraction, ELISA results showed a lower amount 
of C-terminally truncated proteoforms in comparison to N-terminal truncations in all control, sAD 
and rpAD cases. This trend was especially evident in sAD cases where the amount of N-terminally 
truncated Aβ was significantly higher than its C-terminal counterparts, possibly because shorter 
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proteoforms are less prone to aggregation and are frequently formed during the clearance of highly 
aggregated, larger proteoforms. However, FA-soluble fraction showed no significant differences 
among N-terminally and C-terminally truncated pools. 
The lack of a well-defined signature of Aβ proteoforms between sAD and rpAD brains, unaltered 
states of the major proteoforms and non-significant differences in their expression prompted the 
study of aggregation kinetics and structural variations of sAD- and rpAD-derived fibrils. ‘Strain 
theory’ of prion diseases was therefore utilized and Aβ fibrils, purified in their native state via 
ultracentrifugation, were amplified through RT-QuIC assay. The products were thoroughly as-
sessed for structural variations that might be responsible for differences in the progression of the 
targeted clinical subtypes. Although FTIR showed that the secondary structure of Aβ amyloids 
from both subtypes of AD was highly similar, the conversion of monomeric species to β-sheet rich 
fibrils was faster in sAD cases in comparison to rpAD and the latter presented significantly larger 
aggregates highlighting the presence of more hydrophobic Aβ seeds in this group. Additionally, 
the accessory proteins that may contribute towards variation in aggregation kinetics of brain-de-
rived seeds were also identified.  
In the light of these findings, it can be postulated that although the fibrils generated by rpAD brains 
are more hydrophobic and capable of generating larger amorphous aggregates, their conversion 
from seeds to fibrils appears to be slower. During this process, Aβ may exist as more toxic oligo-
meric species for a longer duration and impart greater toxicity on surrounding neurons. The clinical 
phenotype resulting from these changes may, therefore, present a faster rate of progression even 
though the overall profiles of total Aβ in CSF and brain appear highly similar. Collectively, this 
evidence supports that differences in aggregation propensities and hydrophobicity may underlie 
the atypical progression of AD. 
To further the understanding of Aβ-associated alterations in sAD and rpAD brains, a functional 
analysis was also included in this study. An extended treatment of neuronal cells with fibrils gen-
erated via RT-QuIC assay resulted in no significant differences in the survival and confirmed that 
Aβ from sAD and rpAD was equally toxic in its final fibrillar confirmation. The study on human 
samples conducted using co-IP, on the other hand, identified putative interactors involved in 
growth, neurotransmission, metabolism and transport and provided useful insights into different 
functional pathways modulated by Tris-soluble and FA-soluble pools of Aβ. In rpAD cases, Aβ 
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interactors majorly modulated neurotransmission, neurogenesis and protein folding, whereas a ma-
jority of Aβ interactors from sAD brains affected the replication, transcription, translation, 
transport of biomolecules and various metabolic pathways. Owing to the physiological function of 
Aβ, Aβ interactors from control brains modulated pathways involved in immune response and 
maintaining the structural integrity of tissues. 
The hypotheses proposing Aβ as the driving force behind AD are a controversial component of 
AD research in the current era pertaining to the failure of Aβ-targeting therapies. This study sheds 
light on the possible limitations in Aβ research that have been tilting the odds against these hy-
potheses. Studies focused on understanding this peptide on a proteomic level do not explain dif-
ferences in the clinical presentation of AD subtypes nor do they deliver promising results in drug 
trials. No differences were detected in the expression, quantity and processing of major enzymes 
in the current study either. As has been the case with a majority of studies in the last decade, these 
findings can prompt the researchers to turn their attention towards more promising candidates. 
However, examining Aβ under the lens of strain-based differences cannot only validate the in-
volvement of Aβ in the pathophysiology of AD but also contribute towards our understanding of 






6. Appendix A 
 
Figure 32: Comparison of ages at death, post-mortem delay and gender distribution of non-
demented control, sAD, rpAD and CJD samples used in the current study.  No significant 
differences were observed in the (A) ages at death and (B) post-mortem delays in autopsy among 
the samples in the four experimental groups. The relative percentage of females was higher in 
sAD, rpAD and CJD cohorts in comparison to non-demented controls. One-way ANOVA was 





Table 10: Clinical data of brain samples utilized in the current study. 
No. Patient ID Gender Age Braak Stages or Subtype 
1.  Control 1 Male 86 II/A 
2.  Control 2 Male 69 II/A 
3.  Control 3 Male 68 I/0 
4.  Control 4 Male 77 I/A 
5.  Control 5 Male 67 I/0 
6.  Control 6 Female 73 I/0 
7.  Control 7 Male 61 I/0 
8.  Control 8 Male 74 II/A 
9.  sAD 1 Female 56 V/C 
10.  sAD 2 Female 85 V/C 
11.  sAD 3 Female 81 V/C 
12.  sAD 4 Female 81 IV/C 
13.  sAD 5 Female 82 V/B 
14.  sAD 6 Male 81 IV/B 
15.  sAD 7 Male 82 V/C 
16.  sAD 8 Male 66 V/C 
17.  sAD 10 Female 79 I/A 
18.  sAD 11 Female 79 I/A 
19.  sAD 12 Female 86 II/A 
20.  sAD 13 Male 83 III/0 
21.  sAD 14 Female 71 III/0 
22.  sAD 15 Male 64 II/A 
23.  rpAD 1 Male 83 VI/C 
24.  rpAD 2 Female 77 IV 
25.  rpAD 3 Female 85 V 
26.  rpAD 4 Female  85 IV 
27.  rpAD 5 Male  83 VI/C 
28.  rpAD 6 Male  65 - 
29.  rpAD 7 Female 86 - 
30.  rpAD 8 Female 75 III 
31.  sCJD 1   Female 74 VV2 
32.  sCJD 2  Male 66 MM/MV1 
33.  sCJD 3  Female 74 MM/MV1 






Table 11: Observed masses (Da) for Aβ proteoforms identified by MALDI-ToF MS. pAβ 
represents pyroglutamate Aβ proteoforms.  
 Proteoform Observed Mass (Da) Theoretical Mass (Da) 
1.  Aβ1-12 1426.5 1424 
2.  Aβ2-13 1448.6 1446 
3.  Aβ3-14 1515.6 1512 
4.  Aβ2-14 1587.1 1583 
5.  Aβ11-33 2115.9 2111 
6.  Aβ2-20 2349.2 2346 
7.  Aβ15-38 2448.7 2452 
8.  Aβ1-20 2463.0 2461 
9.  Aβ14-38 2584.7 2588 
10.  Aβ5-27 2671.7 2672 
11.  Aβ5-29 2852.3 2857 
12.  Aβ1-26 3017.3 3021 
13.  pAβ11-40 3116.7 3115 
14.  Aβ1-27 3134.5 3134 
15.  pAβ11-42 3317.6 3318 
16.  Aβ11-42 3333.6 3335 
17.  Aβ9-40 3375.7 3372 
18.  Aβ11-43 3434.2 3437 
19.  Aβ8-40 3460.2 3459 
20.  Aβ9-42 3554.2 3557 
21.  Aβ8-42 3643.0 3643 
22.  Aβ1-34 3786.7 3787 
23.  Aβ4-40 4014.4 4014 
24.  Aβ5-42 4050.9 4051 
25.  Aβ1-37 4074.9 4074 
26.  Aβ1-38 4128.3 4132 
27.  Aβ3-40 4145.9 4144 
28.  Aβ4-42 4197.5 4198 
29.  pAβ3-42 4309.8 4310 
30.  Aβ1-40 4327.1 4329 
31.  Aβ2-42 4397.7 4400 
32.  Aβ1-41 4445.0 4443 






Table 12: List of in vitro interactors identified in FA-soluble fraction of sAD (abbreviated as A in the table), rpAD (R) and 
control (C) brain samples. Peptides were identified from 3 pooled biological replicates per experimental group and identifications 
were accepted, if established at a greater than 95.0% confidence while a minimum of two confident peptide identifications and a confi-
dence threshold of 99.0% was required for protein identifications. The localization and functional category of identified Aβ interactors 
was annotated using UniProtKB database. The subset of proteins that co-purified with fibrils in the third MS dataset, have also been 
indicated. ‘Mit’ stands for mitochondria, ‘Nu’ for nucleus, ‘Cy’ for cytoplasm, ‘Cysk’ for cytoskeleton, ‘Mem’ for cell membrane, ‘ER’ 
for endoplasmic reticulum, ‘Ly’ for lysosome and ‘Ex’ for extracellular. The symbol * indicates the presence of different subunits of 
the stated protein complex in the fibrillar fraction.  
Identified Proteins UniProt ID Localization Functional Category Specificity Purified with fibrils 
10 kDa heat shock protein  P61604 Mit Chaperone R No  
14-3-3 protein  P62258 Nu Signal Transduction A, C Yes 
26S proteasome non-ATPase regulatory 
subunit 
O75832 Nu Chaperone, Apoptosis A, R Yes 
28S ribosomal protein  P82663 Mit Translation R No 
39S ribosomal protein  Q9H0U6 Mit Translation, Chaperone A, R No 
4-aminobutyrate aminotransferase  P80404 Mit Neurotransmission R Yes 
55 kDa erythrocyte membrane protein  Q00013 Mem Signal Transduction A, R No 
60S ribosomal protein  P62913 Nu Translation A, R Yes 
Phosphogluconolactonase O95336 Cy Glucose Metabolism  R No 
Abl interactor 1  Q8IZP0 Nu, Cy, Cysk Dendrite growth R Yes 
Abscission/NoCut checkpoint regulator  Q96K21 Cysk Cell division R No 
Acetyl-CoA acetyltransferase Q9BWD1 Mit, Cy Fatty acid metabolism  A No 
Aconitate hydratase Q99798 Mit Glucose metabolism  A, R Yes 
Actin-like protein 6B  O94805 Nu Neurogenesis, Transcription R Yes* 
Activator of 90 kDa heat shock protein 
ATPase  
O95433 ER, Cy Chaperone, Stress response R, C No 
Acyl-CoA dehydrogenase family member 9 Q9H845 Mit Oxidoreductase A No 
Adaptin ear-binding coat-associated pro-
tein 1  
Q8NC96 Mem  Transport R No 
Adenosylhomocysteinase  P23526 Cy Glucose metabolism  A, C Yes 
Adenylate kinase isoenzyme 1  P00568 Mit Energy metabolism R No 
ADP/ATP translocase 1  P12235 Mit Transport A, R Yes 
ADP-ribosylation factor 4 P18085 Golgi Transport A, R Yes 




Alpha-actinin-2  P35609 Cy Apoptosis R, C Yes 
Alpha-crystallin B chain  P02511 Nu Chaperone  All No 
Alpha-enolase  P06733 Nu, Cy Glucose metabolism All Yes 
Amine oxidase  P27338 Mit Oxidoreductase A No 
Amphiphysin  P49418 Cysk Synaptic Transmission R Yes 
Annexin  P50995 Nu Cell cycle, Cell division All Yes 
AP-2 complex subunits  O95782 Mem Transport R Yes 
APC membrane recruitment protein  Q8N7J2 Mem  Signal Transduction R No 
Apolipoprotein D  P05090 Ex Transport A No 
Apolipoprotein E  P02649 Ex Transport R Yes 
Apoptosis-inducing factor 1  O95831 Nu Apoptosis A No 
Arginase-1  P05089 Cy Immunity All No 
Aspartate aminotransferase  P00505 Mem Transport A, R No 
Aspartate-tRNA ligase  P14868 Cy Protein biosynthesis A Yes 
ATP synthase subunit O  P48047 Mit Transport R Yes 
ATPase ASNA1  O43681 Nu, ER Transport R No 
ATP-binding cassette sub-family B member 
8 
Q9NUT2 Mit Transport, ATP Binding A No 
ATP-dependent RNA helicase  Q7Z478 Cy Protein metabolism A, R Yes 
BPI fold-containing family A, B member 1 Q9NP55 Ex Immunity C No 
Breast carcinoma-amplified sequence 1  O75363 Mem  Mylination R No 
Calcium/calmodulin-dependent protein ki-
nase type II subunit α 
Q9UQM7 Mem  Kinase, Transferase R, C Yes 
Calponin-3  Q15417 Cy Cell-cell adhesion  A Yes 
Calreticulin  P27797 Cy, Mem Chaperone A Yes 
cAMP-dependent protein kinase  P10644 Mem Signal Transduction R, C Yes 
Carbonyl reductase 1  P16152 Cy Oxidoreductase R Yes 
Caspase-14  P31944 Nu Differentiation All No 
Catalase  P04040 Peroxisome Stress response  A No 
Cathepsin D  P07339 Ex, Ly Protein processing A, R No 
Caveolae-associated protein 1  Q6NZI2 Nu, Cy Transcription  A, R No 
CB1 cannabinoid receptor-interacting pro-
tein 1  
Q96F85 Mem Signal Transduction R No 
CD44 antigen  P16070 Mem Cell adhesion A No 
CD59 glycoprotein  P13987 Mem Vesicle transport A No 
Cell adhesion molecule 4  Q8NFZ8 Mem Cell adhesion R No 
Charged multivesicular body protein  Q9HD42 Nu, Cy Cell cycle, Transport C No 
Chloride intracellular channel protein 4  Q9Y696 Mem,  Mit Transport A, R No 
Citrate synthase  O75390 Mit Glucose Metabolism All Yes 




Cofilin-1  P23528 Cy, Mem, Nu Signal Transduction All Yes 
Collagen alpha-2(I) chain  P08123 Ex Collagen fibril organization C Yes 
Contactin-1  Q12860 Ex Cell adhesion, cell signalling R, C Yes 
COP9 signalosome complex subunit 4  Q9BT78 Nu DNA damage repair R, C No 
Copine-1 Q99829 Nu, Mem Transcription A, R No 
Corneodesmosin  Q15517 Ex Cell Adhesion All No 
Coronin Q9BR76 Cysk Cytoskeleton organization R No 
Creatine kinase  P06732 Cy Kinase, Transferase All Yes 
CUGBP Elav-like family member 1  Q92879 Nu mRNA processing R Yes 
Cystatin-B and C P04080 Nu Protease inhibitor R Yes 
Cysteine and glycine-rich protein 1  P21291 Nu Platelet aggregation A, R No 
Cytochrome b-c1 complex  P31930 Mit Energy Metabolism  All Yes* 
Cytosol aminopeptidase  P28838 Cy Protein processing A Yes 
Cytosolic non-specific dipeptidase  Q96KP4 Cy Protein processing A, R Yes 
Delta-1-pyrroline-5-carboxylate dehydro-
genase  
P30038 Mit Proline metabolism A No 





P33316 Mit, Nu Nucleotide metabolism A No 
Dihydrolipoyl dehydrogenase  P09622 Mit, Nu Redox homeostasis A, R No 
Dihydrolipoyllysine-residue of pyruvate-de-
hydrogenase complex 
P10515 Mit Carbohydrate metabolism A Yes 
succinyltransferase component of 2-oxoglu-
tarate dehydrogenase complex  
P36957 Mit, Nu Tricarboxylic acid cycle All Yes 
Dihydropteridine reductase  P09417 Cy Protein metabolism R No 
Dihydropyrimidinase-related protein  Q14195 Cy Protein processing R Yes* 
Diphosphoinositol polyphosphate phospho-
hydrolase 2  
Q9NZJ9 Cy Signal Transduction R Yes 
DNA-directed RNApolymerases  O15160 Nu Transcription R No 
DnaJ family A member 2  O60884 Mem Chaperone R No 
DnaJ homolog subfamily B  P25686 Nu, ER Chaperone All Yes 
Drebrin  Q16643 Cy Differentiation, Neurogenesis R No 
Dynactin subunit  Q13561 Cysk Cell cycle All No 
Dynamin-1  Q05193 Cysk Transport R, C Yes 
EH domain-containing protein 2  Q9NZN4 Cy Endocytic recycling A Yes* 
Electron transfer flavoprotein  P13804 Mit Transport A Yes 
Electron transfer flavoprotein-ubiquinone 
oxidoreductase  




Elongation factor  P29692 Nu Protein metabolism, transcrip-
tion 
R, C Yes 
Endophilin Q99962 Cy Endocytosis R, C Yes 
ER chaperone BiP  P11021 ER Chaperone, Hydrolase All Yes 
ER resident protein 29 P30040 ER Transport R Yes 
Endoplasmin  P14625 ER Chaperone R No 
Enoyl-CoA hydratase  P30084 Mit Fatty acid metabolism R Yes 
Erlin-2  O94905 ER Lipid metabolism R, C Yes 
Eukaryotic initiation factor 4A-I  P60842 Cy Host-virus interaction C Yes 
Eukaryotic peptide chain release factor 
subunit 1  
P62495 Cy Protein metabolism A No 
Eukaryotic translation initiation factor P47813 Cy Protein metabolism  All Yes 
F-actin-capping protein subunit P47756 Cysk Cytoskeleton organization R Yes 
Fascin  Q16658 Cysk Cytoskeleton organization A, R Yes 
Fibrinogen  P02679 Ex Hemostasis R, C Yes 
Filaggrin  P20930 Cysk Developmental protein All Yes 
Filamin-C  Q14315 Cysk Cell junction assembly R Yes* 
Flavin reductase  P30043 Cy Oxidoreductase C Yes 
Fructose-bisphosphate aldolase  P04075 Cy Carbohydrate metabolism All Yes 
Fumarate hydratase  P07954 Mit Carbohydrate metabolism R Yes 
Galectin P09382 Ex Apoptosis All Yes 
GABA receptor-associated protein  P60520 Golgi Transport R No 
Gamma-enolase  P09104 Mem  Carbohydrate metabolism All Yes 
Gelsolin  P06396 Ex Cytoskeleton organization R, C No 
Glucose-6-phosphate isomerase  P06744 Ex Carbohydrate metabolism A, R Yes 
Glutamate dehydrogenase  P00367 Mit Carbohydrate metabolism All No 
Glutaminase kidney isoform  O94925 Cy, Mit Glutaminase activity A, C Yes 
Glutamine amidotransferase-like  P0DPI2 Mit - C No 
Glutaredoxin-3  O76003 Cy Homeostasis A No 
Glutathione reductase  P00390 Mit Redox homeostasis R No 
Glutathione S-transferase  P78417 Cy Oxidoreductase, Transferase A, R Yes 
Glyceraldehyde-3-phosphate dehydrogen-
ase  
P04406 Cy, Nu Apoptosis, Translation regula-
tion 
All Yes 
Glycogen phosphorylase  P11217 Cy Carbohydrate metabolism R Yes 
G-rich sequence factor 1  Q12849 Mit mRNA processing R No 
Growth arrest-specific protein 7  O60861 Cysk Differentiation, Neurogenesis R No 
Growth factor receptor-bound protein  P62993 Nu, Golgi Signal transduction All No 
Guanine deaminase  Q9Y2T3 Cy Nervous system development R No 
Guanine nucleotide-binding protein  P62873 Cy, Ly, Mem Signal Transduction All No 




Haptoglobin  P00738 Ex Immunity R No 
Heat shock 70 kDa protein 1A  PDMV8 Nu, Mem Chaperone, Stress response All Yes 
Heat shock 71 kDa protein  P11142 Nu, Mem Chaperone All Yes 
Heat shock protein beta-1  P04792 Nu Chaperone, Stress response All Yes 
Heat shock protein HSP 90  P07900 Nu, Mem Chaperone R, C Yes 
Heme-binding protein 1  Q9NRV9 Cy Signal Transduction A, C No 
Hemoglobin subunit alpha/ beta P69905 Cy, Mem Transport All Yes 
Heparan sulfate proteoglycan core protein  P98160 Ex Angiogenesis A Yes 
Hepatoma-derived growth factor  P51858 Nu Transcription regulation A No 
Heterogeneous nuclear ribonucleoprotein  Q99729 Nu Transcription regulation All Yes 
Hexokinase-1  P19367 Mit Carbohydrate metabolism R No 
Histone deacetylase complex subunit  O00422 Nu Transcription regulation R Yes 
Histone H2A, 2B, H4 P20671 Nu Chromatin organization All Yes 
Histone-binding protein RBBP4  Q09028 Nu Transcription regulation A Yes 
HLA class I antigen  P04439 Mem Immunity A No 
Homer protein homolog  Q86YM7 Mem Transport R, C No 
Hsc70-interacting protein  P50502 Cy Chaperone All No 
Hsp90 co-chaperone Cdc37  Q16543 Nu, Mem Chaperone R, C No 
Hyaluronan and proteoglycan link protein 
2  
Q9GZV7 Ex Cell adhesion R Yes 
Hypoxanthine-guanine phosphoribosyl-
transferase  





P12268 Nu GMP biosynthesis, Purine bio-
synthesis 
R No 
Inter-alpha-trypsin inhibitor  P19823 Ex Protein processing R No 
Interleukin enhancer-binding factor 2  Q12905 Nu Transcription regulation A Yes 
Intracellular hyaluronan-binding protein 4  Q5JVS0 Nu Transcription regulation R No 
IQ motif and SEC7 domain-containing pro-
tein 1  
Q6DN90 Nu Cytoskeleton organization R, C Yes 
Isocitrate dehydrogenase  O75874 Cy Carbohydrate metabolism A Yes 
Junction plakoglobin  P14923 Cysk Cell adhesion All Yes 
Kininogen-1  P01042 Ex Inflammatory response A No 
Lamin-B2  Q03252 Nu Structural molecule activity R Yes 
Leucine-rich repeat flightless-interacting 
protein 2  
Q9Y608 Nu Wnt signaling pathway R No 
Lipoamide acyltransferase component of 
branched-chain alpha-keto acid dehydro-
genase  
P11182 Mit Glyoxylate metabolism  R No 
L-lactate dehydrogenase  P00338 Cy Carbohydrate metabolism R Yes 




Macrophage-capping protein  P40121 Nu Actin capping, Actin-binding A, R No 
MAGUK p55 subfamily member 6 Q9NZW5 Mem  - R Yes 
Major prion protein  P04156 Mem, Golgi Cell cycle, Growth arrest All Yes 
Malate dehydrogenase P40925 Cy Carbohydrate metabolism A, R Yes 
Mammaglobin-B  O75556 Ex Protein processing C No 
Mammalian ependymin-related protein 1  Q9UM22 Ex Cell-matrix adhesion A, R Yes 
MAP6 domain-containing protein 1  Q9H9H5 Cy, Golgi Cytoskeleton organization R No 
Methanethiol oxidase  Q13228 Cy, Mem, Nu Transport A No 
Methionine aminopeptidase 2  P50579 Cy Protein processing R No 
Methylmalonate-semialdehyde dehydro-
genase [acylating]  
Q02252 Mit Protein metabolism A, R No 
Methyltransferase-like 26  Q96S19 - - R No 
MICOS complex subunit MIC Q9NX63 Mit, Nu Transcription regulation C Yes 
Microtubule-associated protein 1 P46821 Cy Cytoskeleton organization R, C Yes 
Microtubule-associated protein 2  P11137 Cysk Cytoskeleton organization R Yes 
Microtubule-associated protein RP/EB 
family member 2  
Q15555 Cysk Cell cycle, Cell division, Mito-
sis 
R Yes 
Microtubule-associated protein tau  P10636 Cysk, Mem Synapse organization A, R Yes 
Mucin-like protein 1  Q96DR8 Ex Signaling pathway A No 
Myc box-dependent-interacting protein 1  O00499 Nu, Mem, Cy Differentiation, Host-virus in-
teraction 
R No 
Myelin proteolipid protein  P60201 Mem Axon development A No 
Myelin-associated glycoprotein  P20916 Mem  Cell adhesion A, R Yes 
Myosin light chain 6B  P14649 Cy Motor protein A, R Yes* 
Myosin-10 P35580 Cy Cell adhesion, Cell shape R, C Yes 
Myosin-binding protein C, cardiac-type  Q14896 Cy Cell adhesion R No 
N(G),N(G)-dimethylarginine dimethyla-
minohydrolase 2  
O95865 Cy, Mit Signal transduction R No 
Na(+)/H(+) exchange regulatory cofactor 
NHE-RF1  
O14745 Cy Wnt signaling pathway R No 
NAD(P) transhydrogenase  Q13423 Mit Redox homeostasis A, R Yes 
NAD-dependent protein deacetylase 
sirtuin-2  





NADH dehydrogenase  Q9P0J0 Nu, Mit Apoptosis, Transport All Yes 
NADH-ubiquinone oxidoreductase  P28331 Mit Transport R Yes 
NADP-dependent malic enzyme  Q16798 Mit Carbohydrate metabolism A Yes 
NADPH:adrenodoxin oxidoreductase  P22570 Mit Lipid metabolism R Yes 
NCK-interacting protein  Q9NZQ3 Nu Cytoskeleton organization R Yes 
Neuroblast differentiation-associated pro-
tein AHNAK  
Q09666 Nu Regulation of voltage-gated 





Neuroendocrine convertase 1  P29120 Cy Release of protein hormones. R No 
Neurofascin  O94856 Mem Cell adhesion C Yes 
Neurogranin  Q92686 Cy Signal transduction R No 
Neuronal-specific septin-3  Q9UH03 Cy Cell cycle, Cell division R, C Yes 
Neutrophil defensin 3  P59666 Ex Antimicrobial, Fungicide A Yes* 




binding protein  
Q15233 Nu Immunity, Transcription regu-
lation 
A, R Yes 
Nuclear distribution protein nudE homolog 
1  
Q9NXR1 Cysk Cell cycle, Neurogenesis R No 
Nuclear migration protein nudC  Q9Y266 Cy, Nu Cell cycle All Yes 
Nucleophosmin  P06748 Nu, Cy Chaperone A Yes 
Osteopontin  P10451 Ex Cell adhesion A No 
Paralemmin-1  O75781 Mem Synapse maturation R Yes 
PDZ and LIM domain protein 7  Q9NR12 Cy Differentiation A No 
Peptide deformylase  Q9HBH1 Mit Protein biosynthesis R No 
Peptidyl-prolyl isomerase P62937 Cy, Ex Protein processing All Yes 
Peptidyl-tRNA hydrolase ICT1  Q14197 Mit Protein biosynthesis R No 
Perilipin-3  O60664 Cy Transport R, C Yes 
Peroxiredoxin Q06830 Cy Redox homeostasis All Yes 
PHD finger protein 24  Q9UPV7 - Neurotransmission R, C Yes 
Phosphate carrier protein  Q00325 Mit Transport A No 
Phosphatidylethanolamine-binding protein 
1  
P30086 Cy Regulation of neurotransmis-
sion 
R, C Yes 
Phosphoglucomutase-1  P36871 Cy Carbohydrate metabolism A No 
Phosphoglycerate kinase 1  P00558 Cy Carbohydrate metabolism A, C Yes 
Phosphoglycerate mutase 1  P18669 Cy, Ex Carbohydrate metabolism R, C Yes 
Phosphoserine aminotransferase  Q9Y617 Cy Amino-acid biosynthesis A No 
PITH domain-containing protein  Q9GZP4 Nu - A, C No 
Platelet-activating factor acetylhydrolase 
IB subunit beta  
P68402 Cy Lipid metabolism R Yes 
Plectin  Q15149 Cysk Cysk regulation R, C Yes 
Poly(rC)-binding protein  Q15365 Nu, Cy mRNA Splicing  A Yes 
Polyadenylate-binding protein 2  Q86U42 Nu mRNA processing R Yes 
Prefoldin subunit 3  P61758 Nu Chaperone A,R No 
Prelamin  P02545 Nu Regulation of chaperone genes All Yes 
Profilin P07737 Cysk Protein processing R Yes 
Prohibitin  P35232 Mit DNA synthesis A,R Yes 




Propionyl-CoA carboxylase P05165 Mit Biotin metabolic process A, R Yes 
ProSAAS  Q9UHG2 Golgi neuropeptide signaling path-
way 
C Yes 
Prosaposin  P07602 Ly Lipid metabolism A Yes 
Proteasome subunit beta type-4  P28070 Nu Protein processing R No 
Protein ABHD14B  Q96IU4 Nu Transcription regulation  All No 
Protein AMBP  P02760 Ex Protein metabolism A No 
Protein disulfide-isomerase  P07237 ER Chaperone All Yes 
Protein kinase C  Q9BY11 Cy Endocytosis R, C Yes 
Protein NDRG1  Q92597 Nu, Cy Signal transduction R Yes 
Protein RUFY3  Q7L099 Cy Differentiation, Neurogenesis R Yes 
Protein S100-A7  P31151 Cy, Ex Immune response A No 
Protein S100-A8  P05109 Ex Immune response A, R Yes 
Protein SET  Q01105 Nu, Cy, ER Chaperone A No 
Protein SOGA3  Q5TF21 Mem Autophagy R No 
Protein unc-119 homolog B  A6NIH7 Cy Transport R No 
Protein/nucleic acid deglycase DJ-1  Q99497 Mit, Mem, Nu Stress response, Chaperone A, R No 
Protein-L-isoaspartate(D-aspartate) O-me-
thyltransferase  
P22061 Cy Protein processing All Yes 
Proteolipid protein 2  Q04941 Mem Transport A No 
Pyruvate dehydrogenase E1 component 
subunit alpha  
P08559 Mit Carbohydrate metabolism A, R Yes 
Ras GTPase-activating protein-binding 
protein 2  
Q9UN86 Cy Stress granule assembly R Yes 
Ras-related protein Rab-7a  P51149 Ly Autophagy, Transport A Yes 
Ras-related protein Ral-A  P11233 Mem Cell cycle, Exocytosis R Yes 
Reticulocalbin-1  Q15293 ER Protein metabolism A Yes 
Reticulon-4  Q9NQC3 ER, Mem  Neurogenesis A, R Yes* 
Ribosome-recycling factor  Q96E11 Mit Protein biosynthesis R No 
RNA-binding motif protein  P38159 Nu mRNA processing, Transcrip-
tion 
A, R No 
RNA-binding protein Raly  Q9UKM9 Nu mRNA processing A Yes 
RuvB-like 1  Q9Y265 Nu DNA repair A, R Yes 
Sarcalumenin  Q86TD4 ER Transport A Yes 
Sarcoplasmic/ER calcium ATPase P16615 ER Transport A, R Yes 
Secretoglobin family 1D member 2  O95969 Ex Transcriptional regulation  A No 
Septin Q9NVA2 Cysk Cell cycle All Yes 
Serine hydroxymethyltransferase  P34897 Nu, Mit, Cy One-carbon metabolism A, R No 
Serine protease HTRA1  Q92743 Cy, Ex Protein processing R No 




Serine/threonine-protein phosphatase  P30153 Mem Chromosome partition A, R Yes 
Serine-threonine kinase receptor-associated 
protein  
Q9Y3F4 Nu mRNA processing A Yes 
Shootin-1  A0MZ66 Cysk Developmental protein R, C No 
Single-stranded DNA-binding protein  Q04837 Mit DNA replication R Yes 
Sodium/potassium-transporting ATPase 
subunits 
P05023 Mem Transport A, R Yes 
Solute-carrier family 12 member 5  Q9H2X9 Mem Transport R Yes 
SPARC-related modular calcium-binding 
protein 1  
Q9H4F8 Ex Differentiation R No 
Spliceosome RNA helicase  Q13838 Nu mRNA processing, Transport A No 
Splicing factor  Q12874 Nu mRNA splicing R Yes 
Stomatin-like protein 2  Q9UJZ1 Mit, Mem Mitochondrial fusion R Yes 
Stress-70 protein  P38646 Nu, Mit Chaperone A,R Yes 
Submaxillary gland androgen-regulated 
protein 3B  
P02814 Ex Pain perception R No 
Succinate--CoA ligase subunit β  Q9P2R7 Mit Carbohydrate metabolism R Yes 
Succinate-semialdehyde dehydrogenase  P51649 Mit GABA metabolism R, C Yes 
Succinyl-CoA:3-ketoacid coenzyme A 
transferase 1  
P55809 Mit Protein processing A, R Yes 
Sulfite oxidase  P51687 Mit Nitrate assimilation R No 
Superoxide dismutase [Mn]  P04179 Mit Superoxide metabolism R, C Yes 
Suprabasin  Q6UWP8 Ex - R, C No 
Synapsin P17600 Golgi Neurotransmitter secretion R Yes 
Syntaxin-binding protein  P61764 Cy Transport R, C Yes 
T-complex protein 1  P17987 Cy Chaperone A, R Yes 
TGF-beta-activated kinase 1 Q15750 Nu, Cy Protein processing R No 
Thioredoxin  P10599 Nu, Sec Transcription regulation A No 
Thioredoxin domain-containing protein 5  Q8NBS9 ER Cell survival R No 
THO complex subunit 4  Q86V81 Cy Chaperone R No 
Thymidine phosphorylase  P19971 Cy Angiogenesis A No 
Thymidylate kinase  P23919 Nu, Cy, Mit Nucleotide biosynthesis C No 
Transaldolase  P37837 Cy Carbohydrate metabolism A No 
Transcription factor A  Q00059 Mit Transcription regulation R No 
Transcriptional activator protein Pur-al-
pha  
Q00577 Nu Transcription regulation R, C No 
Transformer-2 protein homolog beta  P62995 Nu mRNA processing A Yes 
Transforming protein RhoA  P61586 Mem Cell cycle A, R No 
Transgelin-3  Q9UI15 Nu, Cy Development R Yes 




Transketolase  P29401 Nu, Ex, Cy Carbohydrate metabolism A Yes 
Transmembrane emp24 domain-containing 
protein 10  
P49755 ER, Golgi Protein transport A Yes 
Trifunctional enzyme subunit α P40939 Mit Fatty acid metabolism A Yes 
Triosephosphate isomerase  P60174 Cy Gluconeogenesis, Glycolysis All Yes 
Tripeptidyl-peptidase 1  O14773 Ly Protein processing R, C Yes 
tRNA-splicing ligase RtcB homolog  Q9Y3I0 Nu tRNA processing A, C Yes 
Tropomodulin-2  Q9NZR1 Cysk synaptic transmission R, C Yes 
Tubulin polymerization-promoting protein  O94811 Cy, Nu microtubule bundle formation R Yes 
Tubulin polymerization-promoting protein 
family member  
Q9BW30 Cy microtubule bundle formation R No 
Tubulin-specific chaperone C  Q15814 Cy Chaperone R No 
Tubulin-specific chaperone cofactor E-like 
protein  
Q5QJ74 Cysk regulator of tubulin stability. R No 
Ubiquitin carboxyl-terminal hydrolase  P54578 Mem Immunity A, R Yes 
Ubiquitin domain-containing protein  O14562 - NF-kappa-B regulator. R No 
Ubiquitin-60S ribosomal protein L40  P62987 Nu Protein processing A, R Yes 
UBX domain-containing protein Q04323 Cy Protein processing R Yes 
UMP-CMP kinase  P30085 Nu Pyrimidine biosynthesis A, R Yes 
Uromodulin  P07911 CM, Sec Ion homeostasis A No 
Uroporphyrinogen-III synthase  P10746 Cy, Mit Heme biosynthesis R No 
UTP--glucose-1-phosphate uridylyltrans-
ferase  
Q16851 Cy Carbohydrate metabolism A, R No 
Vacuolar protein sorting-associated protein 
4A  
Q9UN37 Cy Cell cycle, Transport R Yes 
Versican core protein  P13611 Ex Protein processing All Yes 
Very long-chain specific acyl-CoA dehydro-
genase  
P49748 Mit Fatty acid metabolism A Yes 
Vesicle-fusing ATPase  P46459 Cy Transport R Yes 
Voltage-dependent anion-selective channel 
protein  
P21796 Mem, Mit Apoptosis, Transport All Yes 
V-type proton ATPase subunit E  P36543 Cy Transport R, C Yes 
WAS protein family homolog 2  Q6VEQ5 Cy Transport R No 
WD repeat-containing protein  O75083 Cy Actin filament depolymeriza-
tion 
A, R Yes 
Zinc finger C3H1 domain-containing pro-
tein  
O60293 Nu RNA processing A No 
Zinc-alpha-2-glycoprotein  P25311 Ex Transport All No 
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